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1. INTRODUCTION 
1.1 Hepatocellular carcinoma  
Hepatocellular carcinoma (HCC) represents about 75% of all liver cancer 
cases according to the data of American Cancer Society in 2015 (Moukhadder 
et al., 2017). It is the most common type of primary liver cancer and the second 
leading cause of cancer-related death worldwide. The morbidity and mortality 
of HCC remain high and are showing a trend of global increase (Weinmann et 
al., 2014). HCC can be induced by multiple risk factors and is influenced by 
many etiologies, hence HCC has a complex pathogenesis (Petrick et al., 2018). 
Despite recent improvements in diagnostic methods, surgical techniques, 
chemoradiotherapy, radiotherapy, and targeted agents the long-term survival 
rate for advanced HCC remains dismal (Li et al., 2014). 
1.1.1 Epidemiology and risk factors of hepatocellular carcinoma 
According to the statistical data from the World Health Organization, 0.8 million 
new cases of HCC were diagnosed for the year 2012 (Bertuccio et al., 2017). 
The global epidemiological distribution varies by geographic location due to 
factors of the underlying disease. More than 80% new cases of HCC occurred 
in developing regions such as sub-Saharan Africa and eastern Asia, with 
typical incidence rates of more than 20/100,000 individuals (Mittal and 
El-Serag, 2013). Especially, China comprises more than half of new cases 
recorded with over 55% of diagnosed patients (Lu et al., 2014). Southern 
European countries have mid-incidence levels (10.0-20.0/100,000 individuals), 
whereas, Northern Europe, North America, and Oceania have a relatively low 
incidence of HCC (Gan et al., 2018). However, the incidence of HCC tends to 
increase in developed and developing countries. For instance, the incidence 
rate of HCC has increased from 1.4/100,000 cases/year to 6.2/100,000 cases 
during 1976–1980 in the USA as reported in 2011 by a USA surveillance 
program (Abbas et al., 2014). Control of HBV and hepatitis HCV infections, 
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optimized management of cirrhosis, HCC diagnosis and treatment have 
contributed to the decrease in HCC-related mortality, e.g., Eastern Asia (Yeo et 
al., 2010). However, in some developed regions, e.g. USA, due to alcohol 
consumption, increased obesity, and diabetes HCC mortality increased (Kew, 
2000; Pradat et al., 2018). 
The most common risk factors for HCC development are chronic hepatitis B 
virus (HBV) and hepatitis C virus (HCV) infections. An estimated 80% of all 
HCC cases are due to chronic infection with hepatitis B (HBV) or hepatitis C 
(HCV) viruses (El-Serag, 2012; Rongrui et al., 2014). Chronic HBV and HCV 
infections are mainly responsible for a significant proportion of HCC cases by 
promoting cirrhosis. Approximately 5% of the world population (350~400 
million people) is chronically infected with HBV (Samji et al., 2017). Most of 
these cases are in developing countries, such as Asia (except Japan) and 
Africa. Prospective cohort studies showed a 5- to 100-fold increase in the risk 
of developing HCC among persons chronically infected with HBV (Brechot et 
al., 2000). Instead of HBV, HCV is regarded as the major risk factor for HCC in 
the United States and Europe (Beguelin et al., 2017). 
Other major risk factors include alcoholic liver disease, non-alcoholic 
steatohepatitis (NASH), consumption of aﬂatoxin-contaminated foods, and 
exposure to chemical carcinogens (Sanyal et al., 2010). Heavy alcohol use, 40 
to 60 grams of alcohol daily, significantly increases the risk for HCC and has 
been reported to have synergistic effects with other risk factors (Younossi et al., 
2016). There is more recent recognition that the metabolic syndrome and its 
components such as diabetes and obesity also increase the risk for HCC. 
These patients have a twice higher chance of developing HCC compared to 
those who are not obese and do not have diabetes (Estes et al., 2018; Polesel 
et al., 2009). 
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1.1.2 Molecular pathogenesis of hepatocellular carcinoma 
HCC is a heterogeneous malignancy resulting from diverse risk factors 
mentioned above. The pathogenesis of HCC is a multistep process involving 
the progressive accumulation of complex genetic and epigenetic alternations 
and cellular events (Figure 1.1). Recent evidence suggests that cancer stem 
cells are also involved in hepatocarcinogenesis but this hypothesis is not yet 
supported by consistent data (Liu et al., 2011; Yao and Mishra, 2009). 
 
Figure 1.1: Molecular pathogenesis of hepatocellular carcinoma (HCC). Chronic 
exposure to a hepatitis virus, alcohol abuse or non-alcoholic steatohepatitis leads 
repetitious hepatocyte damage and triggers a vicious cycle of cell death and 
regeneration which caused cirrhosis and subsequently genomic instability including 
gene rearrangements, somatic mutations, copy number alterations, epigenetic 
changes, and growth factor pathway alterations. Progressive accumulation of multiple 
genetic events eventually leads HCC and metastases. Adapted from Dhanasekaran 
and Bandoh 2016 (Dhanasekaran et al., 2016) 
1.1.2.1 Genetic and epigenetic changes 
With advances of the sequencing technique, more and more genomic 
landscapes of HCC have been revealed. Major groups of genes altered during 
the pathogenesis of HCC include DNA damage response, cell cycle control, 
apoptosis, cell-cell interaction and signal transduction-related genes. Common 
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genetic changes include gene mutations, copy number variations, and gene 
rearrangements (Dhanasekaran et al., 2016; Sato and Mori, 2011). TP53 
mutations are a classic example for genetic changes in HCC which are most 
prevalent in HBV- or aflatoxin-related HCC. The frequency of TP53 gene 
mutation in HCC can reach up to 50% in these etiologies (Puisieux and Ozturk, 
1997). TP53 inactivating mutations lead to loss of cell cycle control and 
affected cells are unable to undergo apoptosis which leads to accumulation of 
additional mutations leading to disease progression. Thus, TP53 mutation is 
common in some etiologies and may induce more aggressive development of 
HCC (Liao et al., 2017). Other common somatic mutations involve the 
Wnt/β-catenin pathway such as CTNNB1, AXIN1, and AXIN2 (Tang et al., 
2004). Interestingly, also mutations in non-coding areas of a gene, such as the 
promoter of TERT which occurs about 60% of HCC, may lead to altered gene 
expression, thereby promoting HCC development (Sullivan et al., 2018). Apart 
from mutations, copy number variations may induce the expression of 
oncogenes or reduce the expression of tumor suppressors. For instance, a 
recent study of 125 HCC cases reported that 32% of patients had focal 
amplifications and 40% of patients had focal deletions (Schulze et al., 2016). 
Another form of somatic variation contributing to HCC are chromosomal 
rearrangements that cause gene fusions or gene activation through integration 
of HBV into the host genome (Herath et al., 2006). 
Epigenetic modifications, including DNA methylation, histone modification, and 
chromatin remodeling are active research topics at the moment (Nakamura et 
al., 2018). In addition, epigenetic modifications by non-coding RNAs such as 
microRNA, long non-coding RNAs, and circular RNAs also play a pivotal role 
in hepatocarcinogenesis through regulating their target genes by diverse 
mechanisms (Negrini et al., 2011; Peng et al., 2018). 
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1.1.2.1 Key signaling pathways in hepatocellular carcinoma 
Signaling pathways are not only utilized to explain the molecular pathogenesis 
of HCC but may potentially to be a source of targets for novel therapies. 
Alterations in various signaling pathways are involved in cell proliferation, 
angiogenesis, invasion, and metastasis of HCC (Minguez et al., 2009). Several 
pathways have been studied in depth and observed to be dysregulated in HCC. 
The most frequently reported pathways are (1) pathways governing growth 
factors signaling, such as epidermal growth factor (EGF), platelet-derived 
growth factor (PDGF), insulin-like growth factor (IGF) and hepatocyte growth 
factor (HGF) pathways (Furuse, 2008; Zender et al., 2010); (2) pathways 
associated with angiogenesis such as the vascular endothelial growth factor 
(VEGF) and fibroblast growth factor (FGF) pathways (Finn and Zhu, 2009; 
Morse et al., 2018). (3) Pathways correlated to cell differentiation such as the 
WNT/β-catenin, Hedgehog, and Notch pathways (Pez et al., 2013; Takigawa 
and Brown, 2008). Among others, receptor tyrosine kinases play a major role 
leading to signal transduction by phosphorylation cascades. Aberrant 
activation of receptor tyrosine kinases, including EGFR, HGFR/c-MET, and 
VEGFR, could be frequently observed and plays a key role in the 
pathogenesis of HCC (Fan et al., 2017; Huynh et al., 2011). For example, 
EGFR mutations play a significant role in HCC initiation, hyperactive 
HGFR/c-MET was found in 40% of HCC patients and is associated with 
vascular invasion and poor prognosis; over-expression of VEGFR has been 
shown in HCC and results in poor prognosis by inducing angiogenesis 
(Giordano and Columbano, 2014). 
The main downstream pathways of receptor tyrosine kinases are 
Ras-mitogen-activated protein kinase (RAS/MAPK) and phosphatidylinositol 
3-kinase (PI3K)/AKT kinase signaling pathways (Li et al., 2018). In 
approximately half of all HCC cases, RAS/MAPK and PI3K/AKT kinase 
signaling pathways are induced by receptor tyrosine kinases. RAS/MAPK 
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pathway activation could induce downstream pathway activation, such as 
proto-oncogene cFos and transcription factor AP-1/c-Jun, which may promote 
transcription of genes that drive HCC cell proliferation (Song, 2009). PI3K/AKT 
kinase activation, in turn, activates mammalian target of rapamycin (mTOR) 
pathway which occurs in about 40% of HCC patients (Wang et al., 2018). 
1.1.3 Therapy options 
Multiple treatment options available for HCC depend on the tumor stage, 
patient performance status and liver function reserve. Conventional treatment 
includes curative resection, liver transplantation, radiofrequency ablation 
(RFA), trans-arterial chemoembolization (TACE), radioembolization and 
systemic targeting therapy (Kudo, 2018; Kuyvenhoven et al., 2001). However, 
only resection and liver transplantation are potentially curative. Liver 
transplantation (LT) is considered the best therapeutic option and potentially 
curative treatment for HCC, Unfortunately, only patients within the Milan 
criteria for HCC (one lesion<5 cm or up to 3 lesions with each ≤3 cm) are 
suitable candidates for LT (Costentin et al., 2018). Patients with single nodules, 
good liver function, and no underlying cirrhosis, are considered the ideal 
candidates for surgical resection. In the last decade, satisfactory results have 
been obtained with RFA, which is recommended as a standard of care for the 
patients who are not suitable for surgery but with early-stage tumors (e.g., 
BCLC 0-A). For patients with intermediate-stage HCC (e.g., Child-Pugh class 
A or B), TACE is currently recommended as a standard of care (Tang, 2001). 
Excepting of TACE, radioembolization or selective internal radiation therapy 
(SIRT) has recently emerged as a therapeutic option for these 
intermediate-stage HCC patients (Harris et al., 2018; Llovet et al., 2018). 
However, despite surveillance programs for high-risk patients, most patients 
are diagnosed with advanced stage disease. Systemic targeted therapies, 
which focus on the critical steps of the carcinogenic pathways and limit 
widespread systemic toxicity, bring hope to patients with advanced cancer 
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(Keane et al., 2018). However, compared with other tumor entities, the 
development of systemic targeted therapies in HCC is lagging behind. 
For patients with advanced disease, sorafenib is the only approved therapy. 
But sorafenib has multiple side effects and the overall survival benefit is only 
2-3 months (Mendez-Blanco et al., 2018). Although several novel targeted 
therapies are currently under evaluation in different clinical trials, current 
first-line treatment studies have not achieved positive results , e.g., brivanib, 
linifanib, dovitinib (Fujiwara et al., 2018). Reasons for the lack of effective 
systemic therapies are the high heterogeneity between HCC patient 
subgroups and that the molecular mechanisms underlying HCC pathogenesis 
remain poorly understood, hence identification of novel oncogenic targets in 
HCC has become a research priority, which is also a motivation for the present 
thesis work. 
1.2 c-KIT and carcinoma 
The proto-oncogene c-KIT, also known as stem cell growth factor receptor or 
tyrosine-protein kinase Kit or CD117, is a receptor tyrosine kinase that is 
encoded by the KIT gene (located on 4q12). After binding of its ligand, stem 
cell growth factor (SCF), c-KIT activates various downstream signal 
transduction pathways (Lennartsson and Ronnstrand, 2012). c-KIT expression 
is widely distributed in hematopoietic cells and other tissues, e.g., germ cells, 
mast cells, melanoma cells, and Cajal cells of the gastrointestinal tract(Yoshida 
et al., 2001). As evident by its diverse distribution, c-KIT plays an important 
role in several physiological processes such as erythropoiesis, hematopoiesis, 
lymphopoiesis, pigmentation, and fertility(Klump et al., 2018). In addition, c-KIT 
is deregulated in several diseases, especially in carcinoma. For example, 
excessive c-KIT signaling caused by mutation of epigenetic regulation results 
in leukemia, and tumors of the gastrointestinal tract and germ cells (Stankov et 
al., 2014). Depending on the mechanism of c-KIT is overactivation, c-KIT may 
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therapeutically targeted by kinase inhibitors such as imatinib or sorafenib 
(Abbaspour Babaei et al., 2016). However, little is known about the funtion of 
c-KIT in HCC and to expand clinical exploitation, the c-KIT signal pathway 
needs to be studied in-depth. 
1.2.1 c-KIT gene and protein structure 
The KIT gene is located on chromosome segment 4q11 in humans and is 
comprised of 21 exons, spanning more than 34 kb of the genome (Heinrich et 
al., 2002). The promoter of the KIT gene is located 139 bp upstream of the 
translation initiation codon and contains three functional AP-2 binding sites and 
the transcription factors microphthalmia-associated transcription factor (MITF), 
MYB and ITS2 serve as regulators of c-KIT expression by binding to the 
promoter of KIT(Blume-Jensen et al., 1991). 
c-KIT is a transmembrane protein. The extracellular domain is encoded by 
exons 2~9 of KIT gene and consist of five immunoglobulin-like (lg-like) 
domains followed by a single spanning transmembrane region encoded by 
exon 10 of the KIT gene (Besmer et al., 1986). The intracellular domain of 
c-KIT, comprises a juxtamembrane region, a kinase domain and a 
COOH-terminal tail (Ma et al., 1999). The juxtamembrane region is important 
for c-KIT kinase activity regulation. The kinase domain is divided into two 
subdomains, tyrosine kinase domain 1 and 2, by an about 80 amino acids long 
kinase insert region (Qiu et al., 1988). Alternative splicing of c-KIT mRNA 
results in the occurrence of at least four isoforms of c-KIT in humans. Two of 
these isoforms are characterized by the presence or absence of the four amino 
acids Gly-Asn-Asn-Lys (GNNK) just outside the plasma membrane. In addition, 
two isoforms are defined according to the presence or absence of a single 
serine residue in the kinase insert region of c-KIT (Figure 1.2) (Crosier et al., 
1993; Reith et al., 1991). 
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Figure 1.2: Schematic representation of the c-KIT protein structure. Five 
immunoglobulin-like (lg-like) domains constitute the extracellular domain of c-KIT. 
After the transmembrane domain, intracellular domain starts with the juxtamembrane 
region followed by a kinase domain and ends with a COOH-terminal tail. Adapted 
from Lennartsson and Rönnstrand 2012 (Lennartsson and Ronnstrand, 2012) 
1.2.2 Activation of c-KIT and its downstream pathways 
Activation of c-KIT requires dimerization of monomeric receptor molecules 
which is provoked by ligand binding. The ligand of c-KIT is stem cell factor 
(SCF, also called Steel factor or Kit ligand) which exists both as a 
membrane-bound and soluble form (London et al., 1996). The c-KIT activation 
process is summarized in Figure 1.3 A. In brief, the first three Ig-like domains 
of c-KIT have a complementary shape and are responsible for tight binding to 
SCF. After binding to each other, two additional Ig-like domains drive 
dimerization of two c-KIT monomers (Casteran et al., 2003). Conformational 
changes of the c-KIT extracellular domains results in close proximity of the 
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transmembrane domains of two c-KIT receptors (Broudy et al., 1998). As a 
consequence, the intracellular regions of c-KIT facilitate tyrosine kinase 
activation and consequent transphosphorylation in the juxtamembrane domain 
at Tyr568 and 570, in the tyrosine kinase domains at Tyr823 and 900, in the 
kinase insert region at Tyr703, 721, 730, and 747 and in the COOH-terminal 
tail at Tyr936 (Qiu et al., 1988). The phosphorylation sites in c-KIT and their 
binding partners are shown in Figure 1.3 B. 
To meet the biological needs of transient signaling activity, negative feedback 
regulation of c-KIT’s activation is important. This generally includes 
intracellular degradation of c-KIT, inactivation of the kinase domain by 
phosphorylation of serine residues 821 and 959, and tyrosine 
dephosphorylation caused by phosphatases (Blume-Jensen et al., 1995). 
 
INTRODUCTION 
11 
 
 
Figure 1.3: Schematic representation of SCF-induced c-KIT activation. (A) SCF 
binds to the Ig-like domains 1-3 of c-KIT, followed by binding of the Ig-like domains 4 
and 5 which leads to dimerization of c-KIT. The dimerization brings the intracellular 
regions into proximity of each other, allowing for tyrosine kinase activation and 
transphosphorylation. (B) Depicted are the intracellular region of c-KIT and its 
phosphorylation sites following SCF stimulation. Adapted from Lennartsson and 
Rönnstrand 2012 (Lennartsson and Ronnstrand, 2012). 
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Several downstream signal transduction pathways of c-KIT have been studied 
in different cell lines. Reported pathways include phosphatidylinositol 
3′-kinase/AKT (PI3K/AKT) Signaling, mitogen-activated protein kinase (MAPK) 
Signaling, JAK/STAT Signaling, Src Family Kinase Signaling and 
Phospholipases C and D Signaling (Kim et al., 2016;Qiu et al., 1988). They are 
integrated into a signaling circuit where one pathway may influence others. 
However, these pathways are cell type dependent and not all of the pathways 
described here are activated in different cell types. Rather only some of these 
downstream signaling routs are activated. But c-KIT downstream effectors 
have not yet been studied in all cell linages and a conclusive overview of the 
downstream effector pathways c-KIT is still missing (Herraiz et al., 2011). 
Therefore, the downstream pathways mentioned above are described as 
separate pathways below and in this thesis special emphasis lays on the two 
well-established signaling routes, the PI3-kinase/ AKT and MAPK pathways, 
which were found to be regulated in HCC. 
A. c-KIT and PI3K/AKT Signaling 
After c-KIT activation, phosphatidylinositol 3′-kinase (PI3K) is activated 
through direct binding to phosphorylation site Tyr-721 of c-KIT and indirectly 
through binding to the tyrosine phosphorylated adaptor protein GAB2 (Figure 
1.3 B). Activated PI3K is recruited to the membrane and induces downstream 
signals (Wandzioch et al., 2004). Signal transduction molecules downstream 
of PI3K play a role in cell survival, migration, and angiogenesis. The 
serine/threonine kinase AKT is a key downstream element of PI3K signaling. 
AKT was initially discovered as a viral oncogene that promotes cell survival 
(Whittaker et al., 2010). In response to c-KIT/SCF activation, AKT is activated 
in a PI3K -dependent manner and then induces phosphorylation of Bad, FOXO, 
and activation of nuclear factor kappa-light-chain enhancer of activated B cells 
(NF-κB) (Liu et al., 2010). The later regulates the initiation of apoptosis which 
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could explain how AKT regulates cell survival (An et al., 2017). One of the 
downstream pathways of AKT is the element serine/threonine kinase 
mammalian target of rapamycin (mTOR) pathway. The mTOR complex 1 
(mTORC1) is located downstream of AKT and c-KIT/SCF has been reported to 
induce proliferation by activating mTOR through PI3K/AKT in mesenchymal 
stem cells cells (Lee et al., 2013). 
B. c-KIT and MAPK Signaling 
MAPK signaling is a downstream effector of multiple cell surface receptors 
including the activated c-KIT/SCF pathway. MAPK plays pivotal roles in a 
multitude of biological processes such as cell proliferation and migration, both 
under normal and pathological conditions including carcinoma (Orouji et al., 
2016). In the pathogenesis of carcinoma, three major groups of MAPKs are 
involved: ERK1 and 2 (ERK1/2), p38, and JNK. Consistently stimulation of 
c-KIT has been shown to activate ERK1/2, p38, and JNK (Zhang et al., 2016). 
Among them, ERK1/2 has been studied in more detail: The mechanism of 
ERK1/2 activation downstream of c-KIT appears to be cell-type specific. For 
example, in mature mast cells, c-KIT induces ERK1/2 activation by 
RAS/Raf/Mek1/2 with the assist of additional proteins, e.g., SHC, SOS, and 
SHP2(McDaniel et al., 2008). However, in primitive hematopoietic cells, it 
depends on PI3K (Herraiz et al., 2011). On the other hand, the activation of Src 
family kinase by c-KIT at Tyr570 and Tyr 568 is important for ERK1/2 activation 
but not in all cell types. Many of the proteins downstream of ERK1/2 are 
transcription factors or cytoplasmic substrates (Ueda et al., 2002). p38 has 
also been demonstrated to be activated in response to SCF stimulation. 
c-KIT/SCF induced p38 activation depends on Src family kinase members Fyn, 
PTPα and kinase PAK1 (Samayawardhena et al., 2006). Besides, studies 
suggest that the JNK pathway is activated by c-KIT activity. SFK-dependent 
phosphorylation of GAB2 induced by c-KIT could recruit SHP2 which is critical 
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for the SCF-induced JNK activation. Moreover, adaptor protein Lnk serves as a 
negative regulator for c-KIT-mediated activation of ERK1/2, p38, and JNK 
(Chen et al., 2013). 
1.2.3 The role of c-KIT in carcinogenesis 
Tumor progression is strongly associated with the activity of receptor tyrosine 
kinases and their intracellular signal transduction pathways. Hence as a 
receptor tyrosine kinase, c-KIT signaling has implicated in the pathogenesis of 
carcinogenesis and target-based approaches for cancer treatment (Abrams et 
al., 2018). Progression of various human tumors including gastrointestinal 
stromal tumors (GISTs), mast cell tumors, melanoma, small cell lung 
carcinoma, testicular carcinoma, acute myeloid leukemia, and colorectal 
cancer are strongly associated with the activity of c-KIT and its intracellular 
signal transduction pathways (Abbaspour Babaei et al., 2016; Choudhary et al., 
2016; Lebron et al., 2014). In these tumor entities, different types of 
deregulation of c-KIT such as gain or loss of function, overexpression, and 
point mutations may occur (Longley et al., 2001). Most publications emphasize 
mutations of c-KIT, especially oncogenic mutations. Oncogenic mutations in 
the c-KIT gene are commonly observed in more than 90% of cases of GISTs 
and more than 70% of patients with mast cell tumor (Lin et al., 2006). These 
oncogenic mutations of c-KIT protein can induce downstream phosphorylation 
cascades in an SCF-independent manner, or excessive activation, 
quantitatively and also qualitatively, after SCF-binding (Chen et al., 2013). 
Thus, the downstream pathways which support proliferation, survival, 
apoptosis, migration, and adhesion are continuously activated leading to tumor 
development. Some of the mutations may cause resistance to kinase inhibitors 
hence resulting in poor patient outcome (Papaspyrou et al., 2011). The 
reported mutations of c-KIT were summarized in Figure 1.4. 
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Figure 1.4: The relative abundance and distribution of various reported c-KIT 
mutations in human malignancies are depicted. Exons 11 and 17 are mutation 
hotspots. D816X mutations are the most common mutations. Adapted from 
Lennartsson and Rönnstrand 2012 (Lennartsson and Ronnstrand, 2012) 
As can be noted, most common mutations cluster in exon 11 and exon 17. A 
large proportion of oncogenic c-KIT mutations are in the juxtamembrane 
region, e.g., V560G or within the kinase domain, e.g., D816X (Maier et al., 
2013). However, the exact mechanism behind constitutive activation is not 
very clear and still needs more investigation. Some of the reported 
mechanisms are as follows: Mutations within the kinase domains results in a 
structural change that impedes autoinhibition, e.g., D816V or increase the 
affinity for ATP and hyper-activation, e.g., D816Y (Agarwal et al., 2015; Beghini 
et al., 1998). Mutations in the juxtamembrane region could potentially promote 
dimerization in the absence of SCF, e.g., V560G (Jung et al., 2011; Kitayama 
et al., 1995).  
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Interestingly, instead of gain-of-function mutations, in certain tumors such as 
melanoma, thyroid carcinoma and breast cancer loss-of-function mutations of 
c-KIT were observed. In fact, in metastatic melanoma gain-of-function could 
induce apoptosis (Franceschi et al., 2017;Vita et al., 2014). 
Besides c-KIT mutation, the role of c-KIT protein level changes also has been 
demonstrated. In several tumors, c-KIT overexpression could be detected 
without any mutation. For instance, the concurrent overexpression of c-KIT 
and SCF occur in neuroblastoma, malignant mesothelioma, colorectal 
carcinoma, breast carcinoma, and small-cell lung cancer (Topcagic et al., 
2018). In these cases, upregulated expression of c-KIT could promote cancer 
proliferation and induce resistance to chemotherapy (Abbaspour Babaei et al., 
2016).  
1.2.4 c-KIT-targeted therapies in cancer 
The fact that activating mutations or overexpression of c-KIT are found in 
various types of human cancers has suggests that c-KIT may be a potential 
target for cancer therapy (Demetri, 2001). Imatinib was the first tyrosine kinase 
inhibitor to be used in treating chronic myelogenous leukemia. Later studies 
found that Imatinib can also inhibit c-KIT and benefits patients with GIST 
(Pandey and Kochar, 2012). However, in GIST imatinib is effective for 
wild-type c-KIT and some of the exon11 mutants but ineffective in patients with 
for several other c-KIT mutants, e.g., D816V. Because this mutation causes a 
continuous active conformation of c-KIT, however, Imatinib can only inhibit 
c-KIT in its inactive conformation (Wada et al., 2016). To overcome this issue, 
novel drugs targeting the kinase activity of c-KIT have been developed. For 
example, dasatinib and nilotinib, as second-generation dual-specificity Src/Abl 
inhibitors, could target mutant c-KIT D816V in its active conformation (Tobio et 
al., 2015). Other relevant targeted drugs include sorafenib, sunitinib, and 
axitinib. More details about c-KIT targeted drugs can be found in Abbaspour 
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Babaei’s reports (Abbaspour Babaei et al., 2016). On the other hand, c-KIT is 
also expressed in normal tissues and has crucial functions, thus, inhibition of 
wildtype c-KIT may cause side effects. To target the specific oncogenic 
mutants of c-KIT, a deeper understanding of the c-KIT signaling machinery is a 
prerequisite (Grillo et al., 2018). 
1.2.5 c-KIT in hepatocellular carcinoma 
So far few studies have reported expression changes of c-KIT in HCC patients. 
However, the functional and mechanistic details of c-KIT in HCC are still 
unclear. Chung et al. reported that 25.6% cases of HCC tissues expressed 
c-KIT protein and indicated c-KIT expression might be a good prognostic 
indicator for HCC (Chung et al., 2005). Mansuroglu et al. found that c-KIT 
expression was detected in 70% of HCC tissues by immunohistochemistry. 
They considered the role of c-KIT/SCF pathway in the regulation of the 
proliferative activity of tumorous hepatic cells. But further confirmation was not 
performed in vivo or vitro (Mansuroglu et al., 2009). In contrast, Becker et al., 
only observed a 2.3% c-KIT-positive rate in HCC patients, they suggested that 
c-KIT may not have a significant role in HCC, but they also discussed that this 
low c-KIT-positive rate may result from the quality if antibody (Becker et al., 
2007).  
In addition, c-KIT has been recognized as marker of hepatic progenitor 
cells/stem cells, such as Oval cells. Several studies showed that c-KIT is 
involved in tumorigenic progenitor cells or tumor stem cells in HCC (Wang et 
al., 2014). The occurrence of c-KIT-positive tumor cells and its potential were 
reported by some publications but the mechanism of c-KIT function in normal 
and tumor stem cells has not been elucidated. For instance, Lee et al. found 
c-KIT-positive tumor cells in tumor tissue of 80% of HCCs. Moreover, they 
indicated c-KIT-positive tumor cells might be associated with the progression 
of HBV–associated HCC as progenitor cells (Lee et al., 2005). Belinda et al., 
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found c-KIT inhibition by imatinib attenuates progenitor cell proliferation and 
inhibits HCC formation in mice (Knight et al., 2008). 
Andres’s group described the interactions between TGF-β and c-KIT signaling. 
They demonstrated that a positive TGF-β/c-KIT feedback loop drives tumor 
progression in HCC. In short, aberrant activation of the c-KIT/STAT3 signaling 
axis causes constitutively activated TGF-β/SMAD2-signaling which results in 
worse outcome (Rojas et al., 2016). In order to decipher the role of c-KIT in the 
pathogenesis of HCC and estimate the clinical potential of c-KIT targeted 
treatment, better understanding the functional role of c-KIT and its underlining 
mechanisms in HCC need to be obtained in further studies.
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2. MATERIALS AND METHODS 
2.1 Materials 
2.1.1 Cell line 
Table 2.1: Information of cell lines used 
Cell line Origin Supplier Ordering number 
Cultivation 
medium 
HUH7 Well-differentiated HCC JCRB JCRB0403 DMEM 
HEP3B HCC ATCC ATCC HB-8064 MEM 
HLE Undifferentiated HCC JCRB JCRB0404 DMEM 
SNU-182 HCC, grade III/IV ATCC ATCC CRL-2235 RPMI-1640 
HLF Undifferentiated HCC JCRB JCRB0405 DMEM 
HEK293T 
Human embryonic kidney cells 
expressing SV40 large T antigen 
ATCC ATCC CRL-3216 DMEM 
2.1.2 Plasmids 
Table 2.2: Information of plasmid used 
Plasmid Supplier Ordering number 
pCMV-c-KIT/WT Angelika Fraas, Manuel Grez  
pCMV-c-KIT/C674F Angelika Fraas, Manuel Grez  
pCMV-c-KIT/W262C Angelika Fraas, Manuel Grez  
pDONR-201 ThermoFisher, Dr. Stefan 
Pusch (DKFZ) 
 
pTRIPZ ThermoFisher, Dr. Stefan 
Pusch (DKFZ) 
 
psPAX2  Dr. Didier Trono Addgene #12260 
pMD2.G Dr. Didier Trono Addgene #12259 
2.1.3 Bacteria 
For molecular cloning, competent MACH1mE. coli (High Efficiency) were 
prepared by AG Roessler, Institute of Pathology, Heidelberg, Germany. 
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2.1.4 Enzymes 
Table 2.3 Information of enzymes used 
Enzymes Supplier 
Ordering 
number 
FastDigest Bsp1407I Thermo Fisher Scientific Inc., Waltham, MA, USA FD0933 
Gateway BP Clonase II 
Enzyme mix 
Thermo Fisher Scientific Inc., Waltham, MA, USA 11789-020 
Gateway LR Clonase II 
Enzyme mix 
Thermo Fisher Scientific Inc., Waltham, MA, USA 11791-020 
RevertAid H Minus 
Reverse Transcriptase 
Thermo Fisher Scientific Inc., Waltham, MA, USA EP0452 
2.1.5 Antibodies 
Table 2.4: Information of antibodies used 
Antibodies Species Supplier Ordering 
number 
Dilution 
Primary 
antibodies 
    
c-KIT antibody 
(E1) 
Mouse Santa Cruz Biotechnology Inc., Dallas, 
Texas, USA 
sc-17806 1:200 
p-c-KIT antibody 
(Tyr719) 
Rabbit Cell Signaling Technology, Inc., Boston, 
MA,USA 
3391S 1:1000 
AKT antibody Rabbit Cell Signaling Technology, Inc., Boston, 
MA,USA 
9272S 1:1000 
p-AKT 
antibody(Ser473) 
Rabbit Cell Signaling Technology, Inc., Boston, 
MA,USA 
4060s 1:1000 
STAT1 antibody  Rabbit Cell Signaling Technology, Inc., Boston, 
MA,USA 
9172S 1:1000 
p-STAT1 
antibody 
(Tyr701) 
Rabbit Cell Signaling Technology, Inc., Boston, 
MA,USA 
7649S 1:1000 
STAT3 antibody 
(124H6) 
Mouse Cell Signaling Technology, Inc., Boston, 
MA,USA 
9139S 1:1000 
p-STAT3 
antibody 
(Tyr705) 
Rabbit Cell Signaling Technology, Inc., Boston, 
MA,USA 
9145S 1:1000 
JAK2 antibody 
(D2E12) 
Rabbit Cell Signaling Technology, Inc., Boston, 
MA,USA 
3230S 1:1000 
p-JAK2 antibody 
(Tyr1007/1008) 
Rabbit Cell Signaling Technology, Inc., Boston, 
MA,USA 
3776S 1:1000 
ERK1/2 antibody Rabbit Cell Signaling Technology, Inc., Boston, 9102S 1:1000 
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MA,USA 
p-ERK1/2 
antibody 
(Y204/Y187) 
Mouse Cell Signaling Technology, Inc., Boston, 
MA,USA 
5726S 1:1000 
JNK JNK 
antibody (FL) 
Rabbit Santa Cruz Biotechnology Inc., Dallas, 
Texas, USA 
sc-571 1:100 
p-JNK antibody 
(Thr183/Tyr185) 
Rabbit Cell Signaling Technology, Inc., Boston, 
MA,USA 
9251S 1:1000 
GAPDH Chicken Merck Chemicals GmbH, Darmstadt, 
Germany 
AB2302 1:10000 
Secondary 
antibodies 
    
IRDye 680LT 
anti-mouse IgG 
Donkey LI-COR Biosciences GmbH, Bad 
Homburg, 
Germany 
926-68022 1:20 000 
IRDye 800CW 
anti-mouse IgG 
Donkey  LI-COR Biosciences GmbH, Bad 
Homburg, 
Germany 
926-32212 1:20 000 
IRDye 800CW 
anti-rabbit IgG  
Donkey LI-COR Biosciences GmbH, Bad 
Homburg, 
Germany 
926-32213 1:20 000 
IRDye 800CW 
anti-goat IgG  
Donkey LI-COR Biosciences GmbH, Bad 
Homburg, 
Germany 
926-32214 1:20 000 
2.1.6 Chemicals and kits 
Table 2.5: Information of kits used 
Chemical and kits Supplier 
Ordering 
number 
Nucleo Spin® Gel and PCR 
Clean-up Kit 
MACHEREY-NAGEL, Düren, Germany 740609.250 
Nucleeo Spin
®
 Plasmid Kit MACHEREY-NAGEL, Düren, Germany 740588.250 
PurreYield™ Plasmid Midprep Promega GmbH, Mannheim, Germany A2492 
Extractme
® 
Total RNA Kit DNA-GDAŃSK, Gdańsk, Poland EM09.1-250 
CellTiter-Blue Cell Viability Assay kit Promega GmbH, Mannheim, Germany G8080 
Lipofectamine RNAiMAX 
Transfection Reagent 
Thermo Fisher Scientific Inc., Waltham, MA, 
USA 
13778150 
Lipofectamine 2000 
Transfection Reagent 
Thermo Fisher Scientific Inc., Waltham, MA, 
USA 
11668019 
1 Kb Plus DNA Ladder 
Thermo Fisher Scientific Inc., Waltham, MA, 
USA 
10787018 
Agarose 
Carl Roth GmbH &Co. KG, Karlsruhe, 
Germany 
2267.4 
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Poly-L-lysine hydrobromide (PLL) 
Sigma-Aldrich GmbH, Taufkirchen, 
Germany 
P6282 
Albumin Bovine, 
DNase/RNase-Free (BSA) 
SERVA Electrophoresis GmbH, Heidelberg, 
Germany 
11967.09 
Kanamycin 
Sigma-Aldrich GmbH, Taufkirchen, 
Germany 
60615 
Carbenicillin Carl Roth GmbH, Karlsruhe, Germany 6344.2 
Puromycin 
Thermo Fisher Scientific Inc., Waltham, 
MA, USA 
A1113803 
Ammonium Persulfate (APS) 
Bio-Rad Laboratories GmbH, Munich, 
Germany 
1610700 
TEMED 
Carl Roth GmbH &Co. KG, Karlsruhe, 
Germany 
2367.3 
Bradford Reagent 
Sigma-Aldrich GmbH, Taufkirchen, 
Germany 
B6916 
Milk powder 
Carl Roth GmbH &Co. KG, Karlsruhe, 
Germany 
T145.2 
PhosSTOP 
Roche Diagnostics GmbH, Mannheim, 
Germany 
4906845001 
PageRuler Prestained Protein 
Ladder, 10 to 180 kDa 
Thermo Fisher Scientific Inc., Waltham, 
MA, USA 
26616 
Tween 20 
Carl Roth GmbH &Co. KG, Karlsruhe, 
Germany 
9127.1 
dNTP Mix (10 mM each) 
Thermo Fisher Scientific Inc., Waltham, 
MA, USA 
R0192 
Random Hexamer Primer 
Thermo Fisher Scientific Inc., Waltham, 
MA, USA 
SO142 
RiboLock RNase Inhibitor 
Thermo Fisher Scientific Inc., Waltham, MA, 
USA 
 
EO0382 
Human stem factor 
Thermo Fisher Scientific Inc., Waltham, 
MA, USA  
RP-8631 
Human hepatocyte growth factor R&D Systems, Minneapolis, MN,USA 294-HG 
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2.1.7 Oligonucleotides 
Table 2.6: Information of primers used 
Primers Sequences 5’-3’ 
primers for molecular cloning  
c-KIT-attB1 GGGGACAAGTTTGTACAAAAAAGCAGGCTccATGAGAG
GCGCCAGAGGGGCCTGG 
c-KIT-attB2 GGGGACCACTTTGTACAAGAAAGCTGGGTtTCAGACGT
CGTCGTGCACCAGCAG 
Sequencing primers  
CMV fwd  CGCAAATGGGCGGTAGGCGTG 
M13 fwd (-20)  GTAAAACGACGGCCAGT 
pDONR201-fwd TCGCGTTAACGCTAGCATGGATCTC 
c-KIT _seq_1207 ATTGCCTTCAACGTGTACG 
c-KIT _seq_1945 AACCACATGAACATCGTG 
c-KIT _seq_587 TGAGCGAGAAGTTCATCC 
qRT-PCR primers  
c-KIT Forward: GCACAATGGCACGGTTGAAT 
 Reverse: GGTGTGGGGATGGATTTGCT 
c-KIT (codon optimized) Forward:GCTGATCGGCTTTGTGATCG 
 Reverse:TGCCGTTGATCTCTTCACC 
Snail Forward:CTTCTCTAGGCCCTGGC 
 Reverse:GACAGGAGAAGGGCTCTCG 
Twist Forward:GACAAGCTGAGCAAGATTCAGACC 
 Reverse:CTGGAGGACCTGGTAGAGGAAG 
Vimentin Forward: GAAAGTGTGGCTGCCAAGAACC 
 Reverse: CAGCCTCAGAGAGGTCAGCAA 
E-cadherin Forward: CTTTGACGCCGAGAGCTACA 
 Reverse: TCGACCGGTGCAATCTTCAA 
N-cadherin Forward: TGGCAGCTGGACTTGATCGAG 
 Reverse: GACATCTGTCACTGTGATGACGG 
ZEB1 Forward:GATCCAGCCAAATGGAAATCAG 
 Reverse:CTGAGCTAGTATCTTGTCTTCATC 
ZEB2 Forward: CTTCTGCGACATAAATACGAACAC 
 Reverse:CGCTTTCTTACAAATCTGACAC 
PLXDC1 Forward: CATCCAATGCTGCGCTCTTC 
 Reverse: GTGGCTGCGAAACTTCATGG 
KCNJ2 Forward: CACTTCCACTCCATGTCCCC 
 Reverse: GGGAGCCTTGTGGTTCTACC 
JAM3 Forward: GACAAGTGACCCCAGGATCG 
 Reverse: ACCTCACAGCGATAAAGGGC 
GJA1 Forward: TCTGAGTGCCTGAACTTGCC 
 Reverse: CCCTCCAGCAGTTGAGTAGG 
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2.1.8 Medium and solutions 
Table 2.7: Information of medium and solutions used 
Medium and solutions Supplier Ordering 
number 
DMEM (Dulbecco's Modified 
Eagle Medium 
Sigma-Aldrich GmbH, Taufkirchen, 
Germany 
D5796 
MEM (Minimum Essential 
Medium) 
Sigma-Aldrich GmbH, Taufkirchen, 
Germany 
M4655 
RPMI 1640 (Roswell Park 
Memorial Institute 1640) 
Sigma-Aldrich GmbH, Taufkirchen, 
Germany 
R8758 
Opti-MEM® I Reduced Serum 
Medium 
Thermo Fisher Scientific Inc., Waltham, MA, USA 31985047 
PBS (Dulbecco's phosphate- 
buffered saline 
Thermo Fisher Scientific Inc., Waltham, MA, USA 14190169 
Fetal Bovine Serum, charcoal 
stripped, USDA-approved 
region 
Thermo Fisher Scientific Inc., Waltham, MA, USA  
Trypsin-EDTA solution Sigma-Aldrich GmbH, Taufkirchen, 
Germany 
T3924 
Penicillin-Streptomycin 
Solution (10,000 units ea.) 
Thermo Fisher Scientific Inc., Waltham, MA, 
USA 
15140130 
Dimethyl sulfoxide ≥99.9% Sigma-Aldrich GmbH, Taufkirchen, 
Germany 
D8418 
2.1.9 Buffers and solutions 
Table 2.8: Information of buffers used 
Buffers and 
solutions 
Composition Application 
PBS 
137 mM NaCl, 2.7 mM KCl, 
10 mM Na2HPO4, 1.8 mM KH2PO4 
Cell harvest 
RIPA Buffer 
50 mM Tris-HCl pH 7.4, 150 mM NaCl, 
1% Triton X-100, 1% sodium deoxycholate, 
0,1% SDS, 1 mM EDTA pH 8.0 
Protein isolation 
4x Loading Buffer 
250 mM Tris HCl pH 6.8, 8% SDS, 
40% glycerol, 0.04% bromphenol blue, 
100 mM DTT 
SDS-PAGE 
Running Buffer 
(pH 8.5 – 8.7) 
0.25 M Tris base, 2 M glycine, 1% SDS SDS-PAGE 
Transfer Buffer 
25 mM Tris base, 200 mM glycine, 
20% methanol 
Western Blot 
TBST 25 mM Tris base, 140 mM NaCl, 3 mM KCl, Western Blot 
MATERIALS AND METHODS 
25 
 
0.02% Tween 20 
LB medium 
10 g Bacto-tryptone, 5 g yeast extract, 
10 g NaCl 
Bacteria 
cultivation 
TAE Buffer 
40 mM Tris base, 10 mM EDTA pH 8.0, 
6% acetic acid 
Agarose gel 
 
2.1.10 Equipment 
Table 2.9: Information on equipment used 
Equipment  Company 
AlphaImager MultiImage Light Cabinet Alpha Innotech Corp., San Leandro, CA, USA 
CO2 incubator INCOmed Memmert GmbH + Co. KG, Schwabach, Germany 
DNA Engine PTC 200 BioRad Laboratories GmbH, Munich, Germany 
Eppendorf 5424R Centrifuge Eppendorf AG, Hamburg, Germany 
Eppendorf pipettes Research plus Eppendorf AG, Hamburg, Germany 
FLUOstar Omega Microplate Reader BMG LABTECH GmbH, Ortenberg, Germany 
Fume hood Secuflow Waldner Laboreinrichtungen GmbH & Co. KG, Wangen, 
Germany 
Hettich Universal 32R centrifuge Andreas Hettich GmbH & Co.KG, Tuttlingen, 
Germany 
Inverted Fluorescence Microscope Olympus 
IX81 
Olympus Deutschland GmbH, Hamburg, 
Germany 
NanoDrop ND-1000 Thermo Fisher Scientific Inc., Braunschweig, 
Germany 
Neubauer Counting Chamber Karl Hecht "Assistent" GmbH, Altnau TG, 
Switzerland 
Odyssey Sa Infrared Imaging System LI-COR Biosciences GmbH, Bad Homburg, Germany 
StepOnePlus Real-Time PCR System Thermo Fisher Scientific Inc., Waltham, MA, 
USA 
2.1.11 Software 
Table 2.10: Information on used software 
Software Version Company 
Adobe Photoshop CS5 12.0 Adobe Systems Inc., San José, CA, USA 
Fiji/ImageJ 1.51j8 Schindelin J et al., 2012 
GraphPad Prism  11.00 GraphPad Software, Inc., La Jolla, CA, USA 
Image Studio  3.1.4 LI-COR, Inc., Lincoln, NE, USA 
StepOne Software  2.3 Thermo Fisher Scientific Inc., Waltham, MA, USA 
R Language  3.4.2 R Development Core Team  
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2.2 Methods 
2.2.1 Cell biological methods 
2.2.1.1 Cell culture 
HCC cell lines including HUH7, HEP3B, HLE, SNU-182, HLF, and HEK293T 
cells were used in this study. SNU-182 and HEK293T cells were obtained from 
American Type Culture Collection (ATCC). HUH7, HEP3B, HLE and HLF cells 
obtained from the Japanese Cancer Research Resources Bank (JCRB). 
HUH7, HLE, HLF, and HEK293T cells were cultured in Dulbecco's Modified 
Eagle Medium (DMEM, high glucose). HEP3B cells were cultured in Minimum 
Essential Media (MEM, high glucose). SNU-182 cells were cultured in RPMI 
1640 Medium. All medium was supplemented with 10% fetal calf serum (FCS) 
and 1% Penicillin (100 IU/m)-Streptomycin (100 g/ml) solution. Cells were 
maintained in an incubator with 37C, 5 %CO2, and 95% relative saturation of 
humidity. 
2.2.1.2 Cell seeding and splitting 
Cells were split and seeded into new dishes or plates when they achieved ~80% 
confluence. The medium was discard and cells were washed with PBS. A 
small volume of trypsin-EDTA (0.25%) was added to the cells. After 5-10 min, 
an equal volume of medium containing 10% FCS was added to stop the 
reaction. Then the cell suspension was mixed by pipetting and cells were 
seeded into new dishes or plates. The medium and trypsin volume and density 
of cells used in different culture dishes are shown in Table 2.11. 
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Table 2.11: Cell density and medium volumes for various sizes of cell culture 
dishes and plates 
 Surface area 
(cm
2
) 
Seeding 
density 
Cells at 
confluency 
Trypsin-EDTA 
(mL) 
Growth medium 
(mL) 
Dishes      
100 mm 60 2×10
6
 8×10
6
 2 10 
60 mm 20 0.8×10
6
 3×10
6
 1 4 
Plates      
6-well 10 0.3×10
6
 1.2×10
6
 0.5 2.5 
12-well 4 0.1×10
6
 0.5×10
5
 0.3 1 
96-well 0.3 0.8×10
4
 4×10
4
 0.1 0.2 
2.2.1.3 Cell cryopreservation and thawing 
Surplus cells were frozen as seed stock. Cells were treated with 0.25% 
trypsin-EDTA when achieved ~80% confluence. A cell suspension was 
prepared and centrifuged at 110 x g for 5 min at room temperature. Then, the 
supernatant was discarded, and cells were resuspended using freezing 
medium (Medium: dimethylsulfoxide: FCS=7:2:1). Resuspended cells were 
transferred into a freezing tube, placed in a freezing container and temporarily 
stored at -80 C for 24 h. After 24 h, cells were transferred into liquid nitrogen 
(-196 C) for long-term storage. For thawing, frozen cells were rapidly placed 
in a 37C water bath. Thawed cells were diluted using pre-warmed growth 
medium and seeded in a 100 mm dish at a relatively high density. After 
culturing for 24 h, medium was changed. 
2.2.2 Overexpression c-KIT using a lentiviral expression system 
To generate inducible expression of wild-type or mutant c-KIT (C674F and 
W262C) in HUH7 and HEP3B cells pTRIPZ, a lentiviral vector for 
doxycycline-inducible expression using the Tet-On system was used.  
A. Preparation of pTRIPZ vectors 
Wild-type c-KIT and mutant c-KIT (C674F and W262C) DNA sequence was 
amplified from pCMV-c-KIT/WT, pCMV-c-KIT- C674F or pCMV-c-KIT- W262C 
by PCR with the primers named c-KIT-attB-1 and c-KIT-attB-2, respectively. 
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PCR products were purified using Nucleo Spin® Gel and PCR Clean-up Kit. 
The Gateway Cloning System was used to clone the wild-type and mutant 
c-KIT PCR products into pTRIPZ vectors. By BP reaction, the PCR products 
flanked by attB recombination sites were inserted into pDONR vectors to 
create entry vectors. The product of BP reaction was transformed into bacteria. 
Shortly, the BP reaction and bacteria were incubated on ice for 30 minutes, 
Heat-shocked at 42°C for 30 seconds, 250 µL of S.O.C. medium was added, 
and bacteria were incubated at 37°C for 1 hour with shaking. Then 150 µl of 
the reaction was plated onto kanamycin-selective plates. A single clone was 
picked, and Nucleeo Spin® Plasmid Kit was used to extract the entry vectors. 
Obtained vectors were confirmed by agarose gel electrophoresis and 
sequencing. Primer sequences are shown in Table 2.6). Next, in the LR 
reaction wild-type and mutant c-KIT DNA sequence transferred from the 
pDONR entry vectors to using LR cloning pTRIPZ vectors. After the LR 
reaction, bacteria were transformed and selected on carbenicillin plates. 
pTRIPZ vectors were extracted using a PureYield® Plasmid Midiprep Kit. The 
obtained pTRIPZ vectors were also confirmed by gel electrophoresis and 
sequencing. pTRIPZ vectors were named pTRIPZ-c-KIT/WT, 
pTRIPZ-c-KIT/C674F, and pTRIPZ-c-KIT/W262C, respectively. Meanwhile, to 
create a control vector for further assay, an empty pTRIPZ without CcdB region 
was used. The reaction details about BP and LR reaction was shown in Table 
2.12. More information about Gateway Cloning System can be found on the 
website of Thermofisher: 
(https://www.thermofisher.com/de/en/home/life-science/cloning/gateway-cloni
ng.html). 
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Table 2.12: Reaction mixes for Gateway BP and LR reaction 
Gateway cloning reaction Component Final amount 
BP reaction 
Incubate @25°C overnight 
Stop reaction with 1 µl Proteinase-K 
@37°C for 10 min 
PCR product 40-120 ng 
pDONR vector 100 ng 
BP Clonase II enzyme mix 2 μL 
TE buffer add up to 10μL 
LR reaction 
Incubate @25°C overnight 
Stop reaction with 0.5 µl Proteinase-K 
@37°C for 10 min 
pDONR vector 30 ng 
pDest vector 15 ng 
LR Clonase II enzyme mix 1 μL 
TE buffer add up to 10 μL 
B. Production of lentivirus 
Lentivirus was produced by the psPAX2 and pMD2.G packaging system. 
Firstly, the transfection mixture was prepared. Using Polyethyleneimine (PEI) 
pTRIPZ, psPAX2 and pMD2.G vectors were transfected into HEK293T cells. 
HEK293T cells were seeded into 100 mm dishes at a density of 5x106 per dish 
24 h before transfection and must more than 70% confluence. Transfected 
cells were routinely cultured overnight (37°C, 5% CO2). The following day, the 
medium was removed, and the fresh complete medium was added. Cells were 
incubated for 48 h (37°C, 5% CO2). Then medium containing lentivirus was 
harvested and filtered by a 0.45 μm Millipore filter. According to the different 
sequence inserted into pTRIPZ vectors, lentivirus was named as Lv-control, 
Lv-c-KIT/WT, Lv-c-KIT/C674F and Lv-c-KIT/W262C, respectively. The 
obtained virus may be stored at 4 °C for short periods (hours to days) but was 
frozen at -20 °C or -80 °C for long-term storage. 
C. Cells infection 
HUH7 and HEP3B were seeded into 100 mm dishes and cultured until the 
achieved 70% confluence. Growth medium was removed and 5 mL fresh 
complete medium +5 mL medium containing lentivirus + polybrene was added 
(final concentration:8 μg/ml). Cells were incubated overnight, and the medium 
was removed the following day. After washing with PBS, fresh complete 
medium was added. 
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D. Selection and induction 
Selection started at 48 h after infection. Medium was removed and replace 
with 10 ml fresh growth medium containing puromycin (2 μg/mL). Fresh 
selection medium was added every 48 h. For induction, 2 μg/mL doxycycline 
was added. 
2.2.3 Knock-down using c-KIT siPool 
The siPool technology was utilized to knock-down endogenous c-KIT protein 
levels in HLE, SNU-182 and HLF cells. The siPool tools are composed of 30 
selected siRNA that target c-KIT mRNA. Using the reverse transfection 
protocol c-KIT siPool or control siPool were transfected into cells. For one well 
in 6-well plate, 210 μL Opti-MEM medium and 40 μL c-KIT or control siPool 
(0.20 μM) were pipetted into a reaction tube (siPOOL dilution), mixed well by 
vortexing or pipetting up and down and centrifuged to spin down droplets. In 
parallel, 246 μL Opti-MEM medium and 4 μL Lipofectamine RNAiMAX 
Reagent were added to another reaction tube (RNAiMAX dilution). Both 
reactions were mixed by vortexing or pipetting up and down, combined in a 1:1 
ratio and incubated 10 min at room temperature before transfection. To one 
6-well, 30 000 cells in 1.5 ml together with 500 μL Transfection mix were added. 
Then, cells were cultured at 37C, 5%CO2. For the mRNA level changes by 
qPCR, cells were harvested 24h after transfection for RNA extraction. For 
different analyses (e.g., functional assays or protein analysis), extended 
incubation periods to 48 h and reduced cell seeding density to 15 000 
cells/well. 
2.2.4 Phenotypical analyses  
2.2.4.1 Cell viability assay 
Cell viability assay was performed using the CellTiter-Blue® Cell Viability 
Assay Kit. Control cells, c-KIT overexpressing HUH7 and HEP3B cells, c-KIT 
knock-down HLE, SNU-182, and HLF cells were seeded into 12-well plates at 
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the density of 15 000 cells/well and cultured for 24 h. The cell titer-blue reagent 
was diluted with relevant medium in a 1:10 ratio. Medium in 12-well plates was 
discarded, and 500 μL diluted CellTiter-Blue reagent was added in each well. 
Empty wells with CellTiter-Blue reagent served as blank control. Cells were 
incubated for 1 h under 37C, 5%CO2. After incubation, the CellTiter-Blue 
reagent was moved into 96-well plate (55 μL/well) from the 12-well plate and 
the fluorescence was recorded (560EX/590EM) using Omega Fluostar 
Microplate Reader. Meanwhile, the used 12-well plated was washed using 
PBS and added into fresh medium. Cells were cultured continually until the 
next measurement. The first measurement was defined as day 1, and the 
measurement was repeated after another 24 h, 48h and 72, respectively. In 
total, 4 time points were collected (day 1, 2, 3 and 4). Human stem cell factor 
(HSCF) was added on day 2 as mentioned in the results section. For each 
group, data were normalized by the value obtained from day 1.  
2.2.4.2 Cell migration assay 
The migration ability of cells was estimated using a wound healing assay. 
Control cells, c-KIT overexpressing HUH7 and HEP3B cells, or c-KIT 
knock-down HLE, SNU-182, and HLF cells were seeded into 12-well plates at 
the density of 12 000 cells/well and cultured until confluence achieved 100%. 
The growth surface was gently and slowly scratched with a sterile 100 μL 
pipette tip across the center of the well creating a cross in each well. To 
remove floating cells, each well was washed by PBS. Then, fresh medium 
(with 0% FCS) was added. To increase the migration capacity, hepatocyte 
growth factor (HGF) was added. According to the study design, HSCF was 
also added or not. Images of gaps in each well were taken at 0 h and 24 h 
using a light microscope. The area of the gap was measured using Image J 
software (version 1.51j8).  
2.2.5 Nucleic acid analysis 
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2.2.5.1 RNA extraction and quality control 
Total RNA was extracted from treated cells using Extractme® Total RNA Kit 
following the protocol from manufacturer's instructions. The concentration and 
quality of total RNA were measured using Nano DropTM microvolume 
spectrometer. The RNA samples with high quality were used for cDNA 
synthesis.  
2.2.5.2 Reverse PCR 
For cDNA synthesis, reverse PCR was performed using RevertAid H Minus 
First Strand cDNA Synthesis Kit. The reverse PCR reaction was prepared 
according to Table, and the PCR program was shown in Table 2.13 and 2.14. 
cDNA samples were stored at -20C before real-time fluorescence 
semi-quantification PCR. 
Table 2.13: Reaction mixes for reverse PCR (1x reaction) 
Master Mix 1 Volume (µL) 
Random Hexamer Primer 1  
RNA 1500 ng Variable 
Nuclease-free water up to 12.5 
Total volume 12.5 
Master Mix 2 Volume (µL) 
5 X RT buffer 1 
Ribolock/RNase inhibitor 4 
dNTP’s 0.5 
RT mix RevertAid Minus 1 
Total volume 7.5  
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Table 2.14: Cycling program for reverse PCR 
Step 1 for Master Mix 1 Temperature Time of duration 
 65C 5 min 
Step 2 for Master Mix 1+7.5 µL 
Master Mix 2 
  
 25C 10 min 
cDNA synthesis 42C 2 h 
Terminate the reaction 70 C 10 min 
2.2.5.3 Real-time fluorescence semi-quantification PCR 
cDNA templates obtained from reverse transcription were diluted 1:50 with 
nuclease-free H2O. For real-time fluorescence semi-quantification PCR, the 
prima-QUANT SYBRGreen kit was used. The reaction system was prepared 
according to Table 2.15. All samples were analyzed in triplicates on the 
StepOnePlus Real-Time PCR System using the PCR program shown in Table 
2.16. Serine/arginine-rich splicing factor 4 (SRSF4) was used as an internal 
reference gene. The relative mRNA level of target genes was calculated using 
the 2-ΔΔCT method. All primers were designed using NIH Primer-BLAST online 
tools and obtained from ThermoFisher Scientific (Table 2.6) 
Table 2.15: Reaction mixes for qRT-PCR (1x reaction) 
 Volume (µL) Final concentration 
primaQUANT CYBR mix 5 1X 
Forward Primer (1 µM)  0.8 80 nM 
Reverse Primer (1 µM) 0.8 80 nM 
Template cDNA (1:50) 2 <180 ng 
Nuclease-free water 1.4 - 
Total volume 10 - 
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Table 2.16: Cycling program for qRT-PCR 
PCR step Temperature Time of duration Number of cycles 
Enzyme activation 95 C 15 min 1 
Denaturation  95 C 15s 40 
Primer annealing/ 
amplification 
60 C 1 min 
Melting curve    
Denaturation 95 C 30s 1 
Starting temperature 60 C 30s 1 
Melting step till 95°C in 0.5°C steps 
2.2.6 Protein analysis 
2.2.6.1 Protein isolation, quantification and sample preparation 
Cell culture dishes or plates were placed on ice and washed with ice-cold PBS. 
Adherent cells were scraped off the dishes or plates in RIPA buffer 
supplemented with PhosStop and protease inhibitor using a clean plastic cell 
scraper and subsequently transferred into a microcentrifuge tube. Cells were 
lysedfor 30 min on ice. After centrifugation for 15 min at 14 000 x g, 4°C, the 
supernatant was transferred to a fresh tube and kept on ice. For determination 
of protein concentration, a Bradford assay was performed. Standard curves 
were established using known concentration protein standards (0.1, 0.25, 0.5, 
1.0, 1.2, and 1.5 µg/µl). To denature, protein samples were diluted with a 4x 
loading buffer containing sodium dodecyl sulfate (SDS), and boil at 95 °C for 8 
min.  
2.2.6.2 Western blot analysis 
Bis-polyacrylamide gels were prepared using the recipes shown in Table 2.17. 
Denatured protein samples (30-50 μg/well) and prestained molecular weight 
markers (10 μL/well) were loaded on SDS-PAGE gels. Gel electrophoresis 
started in a standard migration buffer at 80 V for stacking and then changed to 
100 V for resolving. After electrophoresis, gel and membrane are sandwiched 
between sponge and filter paper. Proteins were transferred to an equilibrated 
nitrocellulose membrane in standard transfer buffer at 90 V for 2 h by the wet 
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transfer method. After transfer, the membrane was blocked by 5% defatted 
milk (diluted by TBST) for 1 h at room temperature. Blocked membrane was 
incubated with TBST diluted primary antibodies for 2 h at room temperature or 
12 h at 4 C. The antibodies information was shown in Table. GAPDH was 
used as a reference. Then the membrane was washed by TBST 3 times and 
each time 10 min. After that membrane was incubated with IRDye secondary 
antibodies for 2 h at room temperature. Protein bands were detected using the 
LI-COR Odyssey Imaging System and quantified using Image Studio software. 
Table 2.17: Recipes for stacking and resolving gels for SDS-PAGE 
 resolving gel  
(8%) 
resolving gel  
(10%) 
Stacking gel 
 (5%) 
1.5 M Tris-HCl, pH 8.8 2.5 mL 2.5 mL - 
1 M Tris-HCl, pH 6.8 - - 380 μL 
30% Acrylamide/Bis-acrylamide 2.7 mL 3.3 mL 500 μL 
10% SDS 100 μL 100 μL 30 μL 
10% APS 100 μL 100 μL 30 μL 
TEMED 6 μL 4 μL 3 μL 
distilled H2O 4.6 mL 4 mL 2.1 mL 
2.2.7 Public dataset analysis 
To analysis the c-KIT expression changes and its potential target genes in 
HCC patients, four public HCC datasets (GSE14520, 36376, 76242 and 76297, 
Table 2.18) was downloaded from Gene Expression Omnibus (GEO, 
https://www.ncbi.nlm.nih.gov/geo), analyzed and visualized using R software 
(version3.2.4). Difference expression genes analysis performed by R software 
with limma package obtained from Bioconductor (https://bioconductor.org). 
Survival analysis was performed using R software with the survminer package. 
Heatmaps were drawn using R software with the pheatmap package. GO 
Enrichment Analysis was performed using the data from Gene Ontology 
Consortium (http://geneontology.org) and visualized by the Goplot online tools 
(http://wencke.github.io). The HCC dataset from the Cancer Genome Atlas 
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(TCGA-LIHC) was accessed and analyzed using Gene Expression Profiling 
Interactive Analysis online tools (http://gepia.cancer-pku.cn/).  
Table 2.18: Information for used GEO public datasets used 
Accesion ID Platform 
Sample numbers used 
Non-Tumor Tumor 
GSE14520 Affymetrix Human Genome U133A 2.0 Array  239 247 
GSE36376 Illumina HumanHT-12 V4.0 expression beadchip 193 240 
GSE76427 Illumina HumanHT-12 V4.0 expression beadchip 52 115 
GSE76297 Affymetrix Human Transcriptome Array 2.0 59 62 
GSE22058 Rosetta/Merck Human RSTA Custom Affymetrix 
1.0 microarray 
97 100 
GSE25097 Rosetta/Merck Human RSTA Affymetrix 1.0 
microarray, Custom CDF 
243 268 
2.2.8 Patient samples used for whole exome sequencing in DKFZ-HIPO 
project 
Whole exome sequencing was performed by the DKFZ-HIPO (Heidelberg 
Center for Personalized Oncology) project 14 using a cohort of 57 
hepatocellular carcinoma patients of which fresh frozen tumor and paired 
non-tumor tissues were available. All tissue samples were provided by the 
Tissue Bank of the National Center for Tumor Diseases (NCT, Heidelberg, 
Germany) in accordance with the regulations of the NCT Tissue Bank. 
Informed consent in writing was obtained from each patient. The study protocol 
conformed to the ethical guidelines of the 1975 Declaration of Helsinki and 
was approval of the ethics committee of the Heidelberg University (S-206/2005, 
S-207/2005 and S-539/2012). Within the presented thesis the finalized results 
of c-KIT mutations were obtained from Matthias Bieg (DKFZ, Heidelberg) 
2.2.9 Statistical analyses 
Statistical analyses were performed by R software (version 3.4.2) and 
GraphPad Prism (version 11.0) built-in statistical analysis function. Normal 
distribution data was shown as mean±SD. Non-normal data distribution was 
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presented as median. According to the character of data, for estimating 
differences between the groups one-way analysis of variance, unpaired t-test, 
and Mann-Whitney U test were used. Survival analysis was performed by 
Kaplan–Meier method followed with the log-rank test. A P value<0.05 
suggested the statistical difference. 
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3. RESULTS 
3.1 Expression of c-KIT in HCC tissue samples and its clinical relevance 
To explore the expression alteration of c-KIT in tissue samples from patients 
with HCC and to identify its correlation with clinical features and prognosis, 
four publicly available gene microarray datasets derived from tissues of 
patients with HCC (accession ID: GSE14520, GSE36376, GSE76427 and 
GSE76297, more details see Table 2.2.6) were retrieved from the Gene 
Expression Omnibus database. As shown in Figure 3.1A, among the four 
datasets, c-KIT expression was slightly but statistical significant higher in 
tumor tissue, compared with non-tumor tissue (P<0.05). According to the 
Barcelona clinic liver cancer (BCLC) staging system and the Cancer of the 
Liver Italian Program (CLIP) staging system, patients in dataset GSE14520 
were divided into two groups including early stage (BCLC stage 0-A or CLIP 
stage 0-2) and advanced stage (BCLC stage B-C or CLIP stage 3-5). In the 
tumor tissue samples from advanced stage patients, the c-KIT level was higher 
compared with early stage patients (P<0.05; Figure 3.1B). Moreover, using 
the median of c-KIT expression as a cut-off, patients in GSE14520 and the 
TCGA HCC dataset (TCGA-LIHC) were divided into two groups. Kaplan-Meier 
analysis followed with Log-rank test was performed to determine the difference 
in survival between patients with high c-KIT level and patients with low c-KIT 
level. This showed that patients with higher c-KIT level had poor prognosis 
(Figure 3.1C; P<0.05). These observations in HCC patients suggested that 
c-KIT may play a role in the progress of HCC. Thus, further functional and 
molecular mechanisms are worth investigating. 
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Figure 3.1: c-KIT expression is higher in tumor compared to non-tumor tissues 
from patients with HCC and is correlated with clinical characteristics. (A) The 
expression difference of c-KIT between tumor and non-tumor tissues was compared 
in multiple microarray datasets of patients with HCC retrieved from Gene Expression 
Omnibus with accession IDs: GSE14520, GSE36376, GSE76427, and GSE76297. All 
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of four datasets show statistically significant higher c-KIT level in tumor tissues. 
*P<0.05 compared with non-tumor tissues. (B) In dataset GSE14520, c-KIT was 
associated with advanced stage. In the BCLC and CLIP stage system, the c-KIT level 
was higher in tumor tissues from patients of advanced stage. *P<0.05 compared with 
early-stage patients. (C) In GSE14520 and TCGA-LIHC datasets, patients were 
divided into two groups using the median of c-KIT level in tumor tissues as a cut-off 
value. 
3.2 Mutations of c-KIT in tissue samples from patients with HCC  
Oncogenic mutations of c-KIT have been shown to be critically involved in the 
development of several of carcinomas. But c-KIT mutations have not yet been 
studied in HCC so far. In project 14 of the Heidelberg Center for Personalized 
Oncology (HIPO) program, whole exome sequencing of 57 HCC patients was 
performed and three c-KIT mutations were observed. The possible impact of 
these three mutations on the structure and function of c-KIT protein was 
predicted by Polymorphism Phenotyping software (version 2.0; Figure 3.2A). 
The PolyPhen-2 scores of mutation W262C and C674F are 0.955 and 1.000, 
respectively, which indicated they are most likely damaging mutations. 
Mutation L762I was predicted as a benign mutation as evident by score 0. 
Furthermore, all observed mutations were confirmed to be somatic in tumor 
and non-tumor tissues from patients with HCC using by Sanger sequencing. 
As shown in Figure 3.2B, all three mutations were only present in the 
respective tumor tissues. The position of W262C, C674F and L766I mutations 
in the c-KIT protein are shown in Figure 3.3C. Mutation C674F is located in 
exon 14 of the c-KIT gene (G2021T) and is accordingly located in the kinase 
domain of the c-KIT protein. This suggests that C674F may affect the kinase 
activity of c-KIT. Mutation W262C within exon 5 on the other hand may have an 
influence on the lg-like domain of the c-KIT protein. Based on this evidence, I 
hypothesized that mutation C674F and W262C might induce altered activation 
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of c-KIT signaling in HCC. The effect of thess two mutations was determined 
by in vitro experiments (see below). 
 
Figure 3.2: Mutations of c-KIT were detected in tissue samples from patients 
with HCC by whole exome sequencing. (A) c-KIT mutations were detected in 3 of 
57 HCC patients. The possible impact of amino acid substitutions in these 3 mutations 
on the structure and function of c-KIT protein was predicted by Polymorphism 
Phenotyping software PolyPhen v2.0. W262C and C674F mutations were predicted 
as damaging amino acid substitutions. (B) All mutations were confirmed by Sanger 
sequencing and were only observed in tumor tissues of HCC patients. (C) The 
position of W262C, C674F and L766I mutations in the c-KIT protein domains are 
depicted. 
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In the Cancer Genome Atlas Liver Hepatocellular Carcinoma (TCGA-LIHC) data, ten 
mutations were found in 357 patients with HCC (Table 3.1). The somatic mutation 
frequency was 2.8%. Among ten mutations, P573Q and D696Y were identified as 
oncogenic mutations and the other mutations have unknown clinical implications. 
Table 3.1 Mutations of c-KIT observed in TCGA-LIHC dataset 
Sample ID Protein Change Mutation Type 
Mutation numbers in 
Sample 
TCGA-ZP-A9D4-01 P141S Missense_Mutation 61 
TCGA-UB-AA0U-01 D696Y Missense_Mutation 72 
TCGA-DD-AAVP-01 S197L Missense_Mutation 72 
TCGA-DD-AAED-01 T847M Missense_Mutation 59 
TCGA-DD-A73D-01 X935_splice Splice_Site 66 
TCGA-DD-A11D-01 P754S Missense_Mutation 112 
TCGA-CC-A8HT-01 D765G Missense_Mutation 184 
TCGA-CC-A7IH-01 S197* Nonsense_Mutation 685 
TCGA-CC-A5UD-01 P573Q Missense_Mutation 185 
TCGA-CC-5264-01 C809* Nonsense_Mutation 90 
3.3 Expression of c-KIT in HCC cell lines 
To select appropriate HCC cell lines for functional analyses and further 
experiments the endogenous expression of c-KIT in HCC cell lines was 
detected by qRT-PCR and Western blot in nine different HCC cell lines 
including HEPG2, HLF, HLE, HUH1, HUH6, HUH7, SNU182, SNU387, HEP3B 
and the immortalized normal hepatocyte cell line HHT4. The relative mRNA 
level of c-KIT in HCC cells was normalized to the house keeper GAPDH and 
subsequently to the value of HHT4 cells as reference. In addition, c-KIT protein 
expression in the same HCC cell lines was measured by Western blot. Botch 
mRNA and protein expression exhibited large differences among the cell lines 
tested. HLE, HLF, and SNU-182 showed clear expression at the mRNA and 
endogenous protein level (Figure 3.3 A & B). In the other cell lines, the mRNA 
level of c-KIT was extremely low and endogenous protein bands were not 
detectable. Thus, HUH7 and HEP3B cells were selected for c-KIT 
RESULTS 
43 
 
overexpression experiments, whereas, HLE, HLF, and SNU-182 were utilized 
for c-KIT knock-down experiments. 
 
Figure 3.3: Endogenous expression of c-KIT in HCC cell lines. (A) mRNA level of 
c-KIT in HCC cell lines was measured by qRT-PCR. The CT value was normalized by 
GAPDH, and then the fold changes relative to HHT4 cells were calculated by the delta 
delta CT method. (B) c-KIT protein expression in HCC cell lines was detected by 
Western blot. In accordance with the mRNA results, only in HLF, HLE and SNU-182 
cell lines showed detectable c-KIT protein expression. 
3.4 Effect overexpression and mutations of c-KIT on relevant 
downstream pathways in HCC cell lines  
As a tyrosine kinase receptor, c-KIT mainly acts by regulating its downstream 
pathways. Both aberrant expression and mutation of c-KIT may cause 
pathological downstream signal transduction subsequently promoting the 
initiation or progression of carcinoma. However, the situation about c-KIT and 
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its downstream pathway are still unclear in HCC. In this work, three typical 
c-KIT downstream signaling pathways including AKT, MAPK and JAK/STAT 
were investigated. Due to undetectable endogenous c-KIT expression, 
wild-type c-KIT was overexpressed in HUH7 and HEP3B. To identify the 
feature of c-KIT mutation C674F and W262C, c-KIT containing these two 
mutations was also expressed in HUH7 and HEP3B cell lines, respectively. On 
the other hand, the c-KIT expression was knocked down in HLE, SNU-182 and 
HLF cells using c-KIT-siPooL which is a mixture of 30 selected different 
siRNAs. To obtain a comparable baseline of phosphorylation level, all cells 
were starved in serum-free medium for 24 h before Western blotting to detect 
the phosphorylation level of target pathways. To activate c-KIT signaling, cells 
were incubated with 100 ng/mL human stem cell factor (HSCF) for 15 min prior 
to harvesting cells for analysis. The time of duration for stimulation was 
decided by preliminary experiment. Either shorter or longer time could weaken 
the detectable phosphorylation of target components.  
For overexpression of c-KIT wildtype, c-KIT C674F or c-KIT W262C a lentiviral 
inducible system was used to ensure homogeneous and consistent expression 
with minimal selection pressure on the respective cells. The doxycycline 
(Dox)-inducible lentiviral expression system effectively induced c-KIT protein 
expression in HUH7 cells (Figure 3.4). HSCF treatment for 15 min induced 
significant phosphorylation of c-KIT at Tyr791. Compared with c-KIT/WT and c- 
Kit-CF (C674F mutation), cells expressing c-KIT-WC (W262C mutation) 
showed lower p-c-KIT-Tyr791 (p-c-KIT) level (P<0.05). Furthermore, HSCF 
induced phosphorylation of AKT at Serine 473 (p-AKT) in c-KIT 
overexpressing cells. Consistent with the p-c-KIT level, the p-AKT level was 
also lower in cells expressing c-KIT-WC (P<0.05). For statistical analyses, 
band intensities of three independent Western blot experiments were 
quantified and normalized to GAPDH as loading control (Figure 3.4 B). Thus, 
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c-KIT stimulation with HSCF leads to AKT phosphorylation and the 
patient-derived W262C mutation of c-KIT impairs c-KIT/AKT signaling. 
 
Figure 3.4: c-KIT overexpression induced downstream AKT signal transduction 
in HUH7 cells. c-KIT wild-type (WT), C674F and W262C mutant protein expression 
was induced in HUH7 using a pTRIPZ-based doxycycline-inducible lentiviral system. 
Control lentivirus (LV-Ctrl) cells were prepared using empty pTRIPZ vector. (A) Cells 
were treated with 100 ng/mL human stem cell factor (HSCF) for 15 min before protein 
collection. Total c-KIT, phosphorylation level of c-KIT at Tyr791, total AKT and 
phosphorylation of AKT at Ser473 were measured by Western blot. (B) Data of three 
independent experiments were quantified and normalized to HSCF-treated 
LV-c-KIT/WT infected cells. HSCF activated wildtype c-KIT, however, c-KIT/W262C 
had lower effects on phosphorylation of c-KIT compared to c-KIT/WT and 
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c-KIT/C674F. Consistently, in c-KIT/W262C infected HUH7 cells less p-AKT levels 
were observed. *P<0.05 compared to LV-Ctrl infected cells in each of condition. 
#P<0.05 compared to LV- c-KIT/W262C infected cells in each of condition. 
Two routes of MAPK signaling, JNK and ERK1/2, were analyzed in this work 
because they have been implicated in HCC previously. As shown in Figure 3.5, 
the phosphorylation of JNK at Thr183 and Tyr185 (p-JNK) level was increased 
by HSCF stimulation. Similarly to AKT, HUH7 cells expressing c-KIT-WC 
mutant protein showed less pronounced increase of p-JNK levels (P<0.05). 
But no difference in the phosphorylation of ERK1/2 at Tyr204 and Tyr 187 
(p-ERK1/2) level was observed in these conditions. Neither c-KIT 
up-regulation nor HSCF treatment had any effect on the phosphorylation of 
ERK1/2. Thus, c-KIT signaling in the HCC cell lines HuH7 did not affect ERK 
signaling and ERK signaling seemed to be activated by other mechanisms as 
unstimulated cells already displayed basal p-ERK1/2 levles wich could not be 
further augmented. Taken together, JNK signaling is activated by c-KIT 
signaling through stimulation with HSCF but c-KIT mutation W262C led to 
reduced JNK activation. 
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Figure 3.5: c-KIT overexpression influences JNK but not ERK signal 
transduction in HUH7 cells. c-KIT wild-type (WT), C674F and W262C mutant 
protein expression was induced in HUH7 using a pTRIPZ-based 
doxycycline-inducible lentiviral system. Control lentivirus (LV-Ctrl) cells were prepared 
using empty pTRIPZ vector. (A) Cells were treated with 100 ng/mL human stem cell 
factor (HSCF) for 15 min before protein collection. Total JNK, phosphorylation level of 
JNK at Thr183 and Tyr185, total ERK1/2 and phosphorylation of ERK1/2 at Tyr204 
and Tyr 187 were measured by Western blot. (B) Data of three independent 
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experiments were quantified and normalized to HSCF-treated LV-c-KIT/WT infected 
cells. *P<0.05 compared to LV-Ctrl infected cells in each of condition. #P<0.05 
compared to LV- c-KIT/W262C infected cells in each of condition. 
Next, the influence of HSCF/c-KIT signaling on the JAK/STAT pathway was 
studied. The STAT family members STAT1 and STAT3 have been shown 
previously to be involved in HCC. STAT1 is believed to be tumor suppressive, 
whereas, STAT3 acted oncogenic in cell culture experiments and animal 
studies. Thereby, the phosphorylation of STAT proteins is mediated by JAK1, 
JAK2 or TYK2. Using different antibodies, no phosphorylation of JAK1 or TYK2 
could be observed (data not shown). In addition, no alteration in JAK2 total 
protein or phosphorylation could be detected upon c-KIT wildtype or c-KIT 
mutant protein expression (Figure 3.6). STAT1 signaling was activated by 
phosphorylation upon treatment with HSCF in c-KIT wildtype overexpressing 
cells.However, c-KIT-WC showed lower p-STAT1 levels (P<0.05). Interestingly, 
I found treatment with HSCF only without expression of c-KIT induced 
activation of STAT3 in HUH7 control cells. The p-STAT3 level was not 
increased in c-KIT overexpressing cells and the effect of HSCF was lost upon 
c-KIT expression. 
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Figure 3.6: c-KIT overexpression influences STAT1 signal transduction in HUH7 
cells. c-KIT wild-type (WT), C674F and W262C mutant protein expression was 
induced in HUH7 using a pTRIPZ-based doxycycline-inducible lentiviral system. 
Control lentivirus (LV-Ctrl) cells were prepared using empty pTRIPZ vector. (A) Cells 
were treated with 100 ng/mL human stem cell factor (HSCF) for 15 min before protein 
collection. Total JAK2, phosphorylation level of JAK2, total STAT1, phosphorylation of 
STAT1 at Ser701, total STAT3 and phosphorylation of STAT3 at Ser705 were 
measured by Western blot. (B) Data of three independent experiments were 
quantified and normalized to HSCF-treated LV-c-KIT/WT infected cells. *P<0.05 
compared to LV-Ctrl infected cells in each of condition. #P<0.05 compared to LV- 
c-KIT/W262C infected cells in each of condition. 
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To exclude cell line-specific effects observed in c-KIT signaling in the HUH7 
cell line, the same experiments were performed in the HCC cell line HEP3B. 
The results in HEP3B cells were overall similar with HUH7 but still had some 
minor differences. As shown in Figure 3.7, the Dox-inducible lentiviral 
expression systems effectively worked in HEP3B cells. After treatment with 
HSCF, phosphorylated c-KIT followed with activated AKT was observed in 
c-KIT overexpression cells. Comparable to the results in HUH7, c-KIT with 
W262C mutation showed less activity, compared with c-KIT/WT and c-KIT-CF 
(P<0.05). 
 
Figure 3.7: c-KIT overexpression induced downstream AKT signal transduction 
in HEP3B cells. c-KIT wild-type (WT), C674F and W262C mutant protein expression 
was induced in HEP3B using a pTRIPZ-based doxycycline-inducible lentiviral system. 
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Control lentivirus (LV-Ctrl) cells were prepared using empty pTRIPZ vector. (A) Cells 
were treated with 100 ng/mL human stem cell factor (HSCF) for 15 min before protein 
collection. Total c-KIT, phosphorylation level of c-KIT at Tyr791, total AKT and 
phosphorylation of AKT at Ser473 were measured by Western blot. (B) Data of three 
independent experiments were quantified and normalized to HSCF-treated 
LV-c-KIT/WT infected cells. HSCF activated wildtype c-KIT, however, c-KIT/W262C 
had lower effects on phosphorylation of c-KIT compared to c-KIT/WT and 
c-KIT/C674F. Consistently, in c-KIT/W262C infected HEP3B cells less p-AKT levels 
were observed. *P<0.05 compared to LV-Ctrl infected cells in each of condition. 
#P<0.05 compared to LV- c-KIT/W262C infected cells in each of condition. 
Different from HUH7, both JNK and ERK1/2 were activated by HSCF in c-KIT 
expressing HEP3B cells. In c-KIT/WT and c-KIT-CF overexpressing HEP3B 
cells stronger p-JNK and p-ERK1/2 bands were detected after HSCF 
stimulation, compared with control (Figure 3.8, P<0.05). However in c-KIT-WC 
overexpressing HEP3B cells, the phosphorylation of JNK and ERK1/2 was not 
induced. 
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Figure 3.8: c-KIT overexpression influences JNK but not ERK signal 
transduction in HEP3B cells. c-KIT wild-type (WT), C674F and W262C mutant 
protein expression was induced in HEP3B using a pTRIPZ-based 
doxycycline-inducible lentiviral system. Control lentivirus (LV-Ctrl) cells were prepared 
using empty pTRIPZ vector. (A) Cells were treated with 100 ng/mL human stem cell 
factor (HSCF) for 15 min before protein collection. Total JNK, phosphorylation level of 
JNK at Thr183 and Tyr185, total ERK1/2 and phosphorylation of ERK1/2 at Tyr204 
and Tyr 187 were measured by Western blot. (B) Data of three independent 
experiments were quantified and normalized to HSCF-treated LV-c-KIT/WT infected 
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cells. *P<0.05 compared to LV-Ctrl infected cells in each of condition. #P<0.05 
compared to LV- c-KIT/W262C infected cells in each of condition. 
Lastly, the JAK/STAT pathway activation was analyzed in c-KIT-inducible 
HEP3B cells upon HSCF-treatment (Figure 3.9, P<0.05). In contrast to HUH7 
cells, c-KIT/WT expressing HEP3B cells showed an induction of STAT1 and 
STAT3 phosphorylation. However, no statistical difference was found in 
c-KIT-CF and c-KIT-WC compared with control cells. Similarly to HUH7, in 
HEP3B cells no alteration in JAK2 was detected. Thus, STAT1 and STAT3 
signaling was induced in c-KIT/WT expressing cells upon HSCF stimulation 
and both patient-derived c-KIT mutations abrogated this activation. 
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Figure 3.9: c-KIT overexpression influences STAT1 signal transduction in 
HEP3B cells. c-KIT wild-type (WT), C674F and W262C mutant protein expression 
was induced in HEP3B using a pTRIPZ-based doxycycline-inducible lentiviral system. 
Control lentivirus (LV-Ctrl) cells were prepared using empty pTRIPZ vector. (A) Cells 
were treated with 100 ng/mL human stem cell factor (HSCF) for 15 min before protein 
collection. Total JAK2, phosphorylation level of JAK2, total STAT1, phosphorylation of 
STAT1 at Ser701, total STAT3 and phosphorylation of STAT3 at Ser705 were 
measured by Western blot. (B) Data of three independent experiments were 
quantified and normalized to HSCF-treated LV-c-KIT/WT infected cells. *P<0.05 
compared to LV-Ctrl infected cells in each of condition. #P<0.05 compared to LV- 
c-KIT/W262C infected cells in each of condition. 
3.5 Effect of c-KIT knock-down on downstream pathways in HCC cell 
lines  
As the overexpression of c-KIT may impose artifacts due to high level 
expression in a non-physiological situation, the influence of knock-down of 
endogenous c-KIT in HCC cell lines was studied. The activity changes of AKT, 
MAPK and JAK/STAT signaling were measured after c-KIT knock-down in cell 
lines which express c-KIT and most likely enhibit functional downstream 
signaling pathways. As shown in Figure 3.10, siPool effectively silenced the 
c-KIT expression and inhibited the activation of c-KIT caused by HSCF in HLE, 
SNU-182, and HLF cells. Thereby, siPool is a mixture of different siRNAs and it 
has been demonstrated that unspecific effects of single siRNAs are minimized 
by using multiple different siRNAs in the siPool. Therefore, it is sufficient to use 
one siPool sample instead of at least two different conventional siRNAs. As 
expected, HSCF did not induce phosphorylation of AKT in c-KIT knock-down 
cells. In the control cells of HLE, SNU-182 and HLF, however, HSCF activated 
c-KIT through the phosphorylation of c-KIT and subsequently AKT was 
activated by phosphorylation at Ser473. In all three c-KIT knock-down cell lines, 
phosphorylation of AKT after HSCF treatment was significantly reduced. 
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Figure 3.10: c-KIT knock-down inhibited downstream AKT signal transduction 
in HLE, SNU-182 and HLF cells. To knock-down c-KIT a selected siRNA mixture 
(sipool) was transfected into cells. (A) Cells were treated with 100 ng/mL human stem 
cell factor (HSCF) for 15 min before protein collection. Total c-KIT, phosphorylation 
level of c-KIT at Tyr791, total AKT and phosphorylation of AKT at Ser473 were 
measured by Western blot. (B) Data of three independent experiments were 
quantified and normalized to HSCF-treated cells. *P<0.05 compared with c-KIT 
siPool-treated in each of condition. #P<0.05 compared with cells without HSCF 
treatment. 
In all three cell lines expressing endogenous c-KIT, JNK and ERK1/2 were 
activated through phosphorylation upon HSCF treatment. The knock-down of 
c-KIT by c-KIT-siPool treatment antagonized this effect suggesting that c-KIT is 
necessary for JNK and ERK1/2 signaling (Figure 3.11). 
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Figure 3.11: c-KIT knock-down inhibited downstream JNK and ERK1/2 signal 
transduction in HLE, SNU-182 and HLF cells. To knock-down c-KIT a selected 
siRNA mixture (sipool) was transfected into cells. (A) Cells were treated with 100 
ng/mL human stem cell factor (HSCF) for 15 min before protein collection. Total JNK, 
phosphorylation level of JNK at Thr183 and Tyr185, total ERK1/2 and phosphorylation 
of ERK1/2 at Tyr204 and Tyr 187 were measured by Western blot. (B) Data of three 
independent experiments were quantified and normalized to HSCF-treated cells cells. 
*P<0.05 compared with c-KIT siPool-treated in each of condition. #P<0.05 compared 
with cells without HSCF treatment. 
Only slight inconsistent effects were observed on STAT1 and STAT3 signaling. 
In HLE and SNU-182 cells, c-KIT knock-down reduced the activation of JAK2 
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even without the stimulation of HSCF but no effect was detected in HLF cells 
(Figure 3.12). In HLE cells, knock-down of c-KIT reduced HSCF-induced 
p-STAT1 but decreased the p-STAT3 level in an HSCF-independent manner. 
No difference on p-STAT1 was observed in treated SNU-182 and HLF cells. 
Interestingly, HSCF reduced the p-STAT3 level in SNU-182 and HLF even in 
cells with normal c-KIT expression. Thus, only small cell line dependent effects 
have been detected after c-KIT knock-down suggesting that STAT1 and STAT3 
signaling are not crucial downstream effectors of c-KIT signaling. 
 
 
Figure 3.12: c-KIT knock-down had variant effect on JAK/STAT signal 
transduction in HLE, SNU-182 and HLF cells. To knock-down c-KIT a selected 
siRNA mixture (sipool) was transfected into cells. (A) Cells were treated with 100 
ng/mL human stem cell factor (HSCF) for 15 min before protein collection. Total JAK2, 
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phosphorylation level of JAK2, total STAT1, phosphorylation of STAT1 at Ser701, total 
STAT3 and phosphorylation of STAT3 at Ser705 were measured by Western blot. (B) 
Data of three independent experiments were quantified and normalized to 
HSCF-treated cells cells. *P<0.05 compared with c-KIT siPool treated in each of 
condition. #P<0.05 compared with cells without HSCF treatment. 
Taken together, the result of all five cell lines, HUH7, HEP3B, HLE, SNU-182, 
and HLF, suggested that c-KIT could activate AKT, MAPK and partly JAK/STAT 
signaling in HCC cells but not all the element had been involved equally in the 
different cell lines. It should be noted that the effect of activated c-KIT on 
certain specific elements of the downstream pathway was different among 
different HCC cells. In most settings no significant difference between c-KIT 
wildtype and c-KIT/C674F mutation were observed. In contrast, the 
c-KIT/W262C mutation showed a reduced response to HSCF. Hence, this 
indicated that the W262C mutation maybe a loss of function mutation of c-KIT. 
Unlike other tumor entities, the two in HCC tested mutations are not 
hyperactive mutations. 
3.6 The effect of c-KIT expression alteration and mutation on the 
proliferation of HCC cell lines 
It was described in several types of carcinomas that continuous activation of 
downstream signaling induced by abnormal expression or mutation of c-KIT 
could promote the proliferation of tumor cells. The effect of c-KIT/HSCF 
signaling on the proliferation of HCC still needs to be determined. I detected 
the cell viability in c-KIT overexpressing or knock-down HCC cells at four time 
points. The viability data of each day was normalized by day one of the 
respective cell line and normalized to control (Ctrl) virus-infected cells. First, 
HUH7 and HEP3B cells were used for expression of wildtype and mutant c-KIT 
protein. Second, endogenous c-KIT protein was inhibited by siPool-mediated 
knock-down in HLE, SNU-182 and HLF cells. The relative cell viability after 2 
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days showed that neither c-KIT overexpression nor c-KIT knock-down altered 
cell viability. Overexpression of c-KIT, regardless of wild-type or mutations, 
could not increase or inhibit cell viability in HUH7 and HEP3B. Likewise, 
knock-down of c-KIT did not influence the cell viability in HLE, SNU-182 and 
HLF cells. These results were obtained in cell culture medium supplemented 
with 10% FCS which contains SCF. To exclude that additional HSCF 
stimulation is needed, cell culture medium was supplemented with 100 ng/mL 
human stem cell factor (HSCF). However, HSCF stimulation did not induce any 
changes in cell viability of all five HCC cell lines (Figure 3.13). This suggested 
that the activation of c-KIT may not have any effect on the cell proliferation in 
HCC.  
 
Figure 3.13: Relative cell viability of c-KIT overexpression and knock-down in 
HCC cells. (A and B) c-KIT wildtype (WT), C674F and W262C mutant protein 
expression was induced in HUH7 (A) and HEP3B (B) using a pTRIPZ based 
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doxycycline-inducible lentiviral system. (C) The knock-down of c-KIT in HLE, 
SNU-182 and HLF cells was conducted using c-KIT siPool tools. Cells were treated 
with 100 ng/mL human stem cell factor (HSCF) after measurement of day one. 
Relative cell viability at 48 h (cell viability of day 3 / cell viability of day 1) was 
calculated and normalized by Ctrl infected cells. 
3.7 The effect of c-KIT expression alteration and mutations on the 
migration of HCC cell lines 
Since migration is an important feature of HCC progression and regulation of 
migration by c-KIT was reported in colorectal carcinoma cells PMID: 28383479, 
the effect of c-KIT expression alteration and mutation on the migration of HCC 
cell lines was investigated by wound healing assay. To avoid interference 
caused by proliferation, c-KIT up- or down-regulated HCC cells were cultured 
in serum-free medium for 24 h after scratches were performed. To fully 
activated c-KIT, some of the cell groups received treatment with 100ng/mL 
HSCF after scratching. As shown in Figure 3.14, overexpression of c-KIT 
promoted migration of HUH7; this effect was stronger in Lv-c-KIT/WT infected 
cells. Although Lv-c-KIT-CF and Lv-c-KIT-WC infected cells showed 
perceptible promotion on migration, the difference has no statistical 
significance. HSCF treatment could not induce faster migration for c-KIT 
up-regulated HUH7. The results obtained from HEP3B cells were opposite. As 
shown in Figure 3.15, despite HSCF treatment or not, Lv-c-KIT-CF and 
Lv-c-KIT-WC had hardly any effect on migration of HEP3B cells, 
overexpression of c-KIT/WT even inhibited the migration. 
Under the serum-free condition, there was no difference on migration between 
normal c-KIT and c-KIT knock-down HLE, SNU-182 and HLF cells without 
HSCF stimulation. The migration promoting the role of c-KIT emerged when 
HSCF was added. c-KIT knock-down cells did not respond to HSCF (Figure 
3.16 A). One possible reason is that c-KIT signaling might not be fully activated 
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in the serum-free medium due to lack of enough HSCF and limited 
endogenous c-KIT. To prove this hypothesis, another migration assay 
performed on c-KIT knock-down cells cultured in complete medium. As 
expected, c-KIT knock-down cells showed inhibited migration even without the 
treatment of HSCF (Figure 3.16 B). However, HSCF treatment did not extend 
the difference between siPool-ctrl and c-KIT siPool transfected cells. It 
indicated that the SCF present in the supplemented FCS was sufficient to fully 
activated c-KIT. Hence additional HSCF supplementation could not increase 
migration promoted by activation of c-KIT. Taken together, the results obtained 
from the wound healing assay indicated that activation of c-KIT may promote 
migration of HCC cells. The c-KIT mutations C674F and W262C attenuated 
the role of c-KIT on migration compared with wild-type. 
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Figure 3.14: Effect of c-KIT overexpression on migration in HUH7. c-KIT wild-type 
(WT), C674F and W262C mutant proteins were overexpressed in HUH7 cells using a 
pTRIPZ based doxycycline-inducible lentiviral system. Control lentivirus (Lv-Ctrl) was 
prepared from an empty pTRIPZ vector. Cells were treated with 100 ng/mL human 
stem cell factor (HSCF) for 24 h after scratching and cultured in serum-free medium. 
The migration ability was estimated by wound healing assay. (A) Compared with 
LV-Ctrl infected cells, infection of LV-c-KIT/WT promoted migration of HUH7 cells in an 
HSCF independent way. LV-c-KIT/C674F and LV-c-KIT/W262C could also promote 
migration but without statistic difference. (B) Relative migrated area [1-(gap area of 24 
h/ gap area of 0 h)] was calculated. Data were normalized by HSCF-treated and 
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LV-c-KIT/Ctrl infected cells and presented as mean ± SD of technical duplicates. 
*P<0.05 compared with LV-Ctrl infected cells in each of condition. 
 
Figure 3.15: Effect of c-KIT overexpression on migration in HEP3B. c-KIT 
wild-type (WT), C674F and W262C mutant proteins were overexpressed in HEP3B 
cells using a pTRIPZ based doxycycline-inducible lentiviral system. Control lentivirus 
(Lv-Ctrl) was prepared from an empty pTRIPZ vector. Cells were treated with 100 
ng/mL human stem cell factor (HSCF) for 24 h after scratching and cultured in 
serum-free medium. The migration ability was estimated by wound healing assay. (A) 
RESULTS 
64 
 
Compared with LV-Ctrl infected cells, infection of LV-c-KIT/WT promoted migration of 
HEP3B cells in an HSCF independent way. LV-c-KIT/C674F and LV-c-KIT/W262C 
could also promote migration but without statistic difference. (B) Relative migrated 
area [1-(gap area of 24 h/ gap area of 0 h)] was calculated. Data were normalized by 
HSCF-treated and LV-c-KIT/Ctrl infected cells and presented as mean ± SD of 
technical duplicates. *P<0.05 compared with LV-Ctrl infected cells in each of 
condition. 
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Figure 3.16: Effect of c-KIT knock-down on migration in HLE, SNU-182, and HLF. 
The migration ability was estimated by wound healing assay. c-KIT siPool (30 
selected target siRNAs) was used to knock-down c-KIT expression in HLE, SNU-182, 
and HLF. Cells were treated with 100 ng/mL human stem cell factor (HSCF) for 24 h 
after scratching and cultured in serum-free medium (A) or complete medium (B). (A) 
In serum-free medium, HSCF treatment promoted the migration depended on the 
c-KIT expression. Relative migrated area [1-(gap area of 24 h/ gap area of 0 h)] was 
calculated. (B) In complete medium, c-KIT knock-down inhibited cell migration 
independent of additional stimulation with HSCF. Data were normalized by 
HSCF-treated and -control transfected cells and presented as mean ± SD of technical 
duplicates. *P<0.05 compared with control transfected cells in each of condition. 
#P<0.05 compared with control cells without HSCF treatment. 
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3.8 c-KIT regulated epithelial-mesenchymal transition in HCC cell lines 
Epithelial-mesenchymal transition (EMT) is defined as a process by which cell 
polarity and cell-cell adhesion of epithelial cells decreases but cells gain 
migratory and invasive features and acquire a mesenchymal stem cell 
phenotype. EMT plays an important role in migration and coincides with the 
initiation of metastasis during cancer progression. As shown above, c-KIT 
promotes the migration of HCC cell lines. Hence, it was tested whether c-KIT 
may promote migration by inducing EMT. EMT markers were detected in 
c-KIT-overexpressing and in c-KIT-knock-down HCC cells by qRT-PCR. First, 
the effective induction of c-KIT mRNA expression was confirmed in the 
Dox-inducible lentiviral expression system (Lv-c-KIT/WT) in HUH7 and HEP3B 
cells. Then, seven EMT markers including Snail1, Twist1, CDH1 (E-cadherin), 
CDH2 (N-cadherin), Vimentin, ZEB1 and ZEB2 were tested at the mRNA level 
(Figure 3.17 A and B). And it was found that of these 7 EMT genes Twist, 
N-cadherin, and Vimentin significantly increased in c-KIT overexpressing 
HUH7 cells (Figure 3.17 C; P<0.05). However, ZEB1 was the only EMT maker 
with statistically significant alteration in HEP3B (Figure 3.17 D; P<0.05). But 
ZEB1 in contrast to the expected induction of ZEB1, ZEB1 significantly 
decreased in HEP3B upon c-KIT expression. This finding is in line with cell the 
migration results of HEP3B. Thus, the decreased ZEB1 matched the c-KIT 
induced migration changes in HEP3B. 
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Figure 3.17: Epithelial-mesenchymal transition markers in c-KIT overexpressing 
HCC cell lines. (A and B) c-KIT mRNA level effectively increased in Lv-c-KIT/WT 
infected HUH7 and HEP3B cells after doxycycline induction. (C and D) mRNA level of 
Twist, N-cadherin, and Vimentin significantly increased in c-KIT overexpressed c-KIT 
overexpressed HUH7 cells. ZEB1 decreased in c-KIT overexpressed HEP3B cells. 
Data were presented as mean ± SD of technical duplicates. *P<0.05 compared with 
cells without doxycycline induction. 
Next, the expression of these EMT markers was analyzed upon knock-down of 
endogenous c-KIT protein in HCC cell lines. The results obtained from HLE, 
SNU-182 and HLE cells were consistent with the results of HUH7. Knock-down 
of c-KIT significantly inhibited the mRNA levels of Snail1, N-cadherin, Vimentin 
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and ZEB1 (Figure 3.18; P<0.05), compared with control cells. The changes of 
EMT markers indicated that c-KIT induce EMT in HCC cells. 
 
Figure 3.18: Epithelial-mesenchymal transition markers changes in c-KIT 
knock-down HCC cell lines. (A-B)The mRNA of c-KIT was significantly inhibited by 
c-KIT-siPool in HLE, SNU-182 and HLF cells. After Knock-down of c-KIT, mRNA 
levels of Snail1, N-cadherin, Vimentin and ZEB1 significantly declined. Data were 
presented as mean ± SD of technical duplicates. *P<0.05 compared with cells 
transfected siPool control. 
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3.9 Selection and validation for candidate gene regulated by c-KIT  
To select potential target genes of c-KIT four public datasets of HCC patients 
were analyzed using a series of bioinformatic methods and validated by 
qRT-PCR. Three datasets (accession ID: GSE14520, GSE 22058 and 
GSE25097) were retrieved from Gene Expression Omnibus (GEO). More 
details about these three dataset can be found in Table 4.6. Another HCC 
dataset was downloaded from Cancer Genome Atlas (TCGA-LIHC). Firstly, the 
c-KIT level in tumor tissues of HCC patients was estimated. Using the median 
expression of c-KIT as a cut-off value, patients were divided into two groups 
including patients with high c-KIT expression and patients with low c-KIT 
expression in each dataset. The differential gene expression profiles between 
two groups were calculated and genes with fold change>1.2 (P<0.05) were 
selected. As shown in Figure 3.19 A, eight genes were selected through 
intersecting results from each dataset. In all of 3 GEO datasets, these eight 
genes are significantly altered in tumor tissues of HCC patients with high c-KIT 
level (Figure 3.19 B).  
To further filter the 8 genes mentioned above the clinical roles of these genes 
on the prognosis of patients was determined. Overall survival was available in 
datasets GSE14520 and TCGA-LIHC. Thus, patients were grouped according 
to the median expression level of each of the 8 genes, respectively. Kaplan–
Meier curves were drawn followed and statistical analysis was performed 
using the log-rank test. It appeared that higher GJA1, PLXDC1, CXCR7, and 
KCJN2 expression were associated with poor prognosis of HCC patients 
(Figure 3.20 and 3.21).  
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Figure 3.19: Eight potential target genes of c-KIT were selected based on four 
public HCC patients’ datasets. (A) Patients in each dataset were divided into two 
groups according to the median expression level of c-KIT in tumor tissues. Differential 
gene expression of patients with high or low c-KIT expression were selected using 
fold change>1.2, P<0.05 as a criterion. Eight genes fulfilled these criteria and were 
selected after integration of results of the four datasets. (B) The log2 fold change of 
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the 8 selected genes between high and low expression groups in the three GEO 
datasets and TCGA-LIHC dataset. All 8 genes were significantly higher in tumor 
tissues of patients with high c-KIT level. DEG: different expression gene. 
 
Figure 3.20 the correlation of 8 candidate genes with the prognosis of HCC 
patients. Patients with HCC from dataset GSE14520 were grouped into two groups 
using the median of each candidate gene as the cut-off value, respectively.  
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Figure 3.21: the correlation of 8 candidate genes with the prognosis of HCC 
patients. Patients with HCC from TCGA-LIHC dataset were grouped into two groups 
using the median of each candidate gene as the cut-off value, respectively. The 
survival data from TCGA-LIHC dataset was provided by GEPIA online tools.  
In addition, to assess the role of the 8 candidate genes on the patient 
prognosis, univariate and multivariate Cox hazard analysis was performed. 
Univariate Cox hazard analysis showed that 6 of 8 candidate genes may be 
regarded as a risk factor for poor prognosis in HCC patients (Table 3.2). 
Furthermore, multivariate Cox hazard analysis was performed for these 6 
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candidate genes as input (hazard ratio >1.0 and P<0.05). After adjustment for 
confounders, PLXD1 and KCNJ2 were identified as independent risk factors 
for poor prognosis of HCC patients (Table 3.3). 
Table 3.2: Univariate Cox hazard analysis for 8 candidate genes 
 Coefficients Hazard ratio 95% CI P value 
JAM3 0.15 1.17 0.85-1.59 0.329 
GJA1 0.27 1.31 1.09-1.59 0.004 
CXCR7 0.16 1.18 1.01-1.38 0.03 
NID2 0.43 1.54 1.12-2.10 0.006 
PLXDC1 0.26 1.30 1.01-1.67 0.04 
EFNB2 0.29 1.35 1.03-1.76 0.02 
CPA3 0.001 1.01 0.69-1.46 0.96 
KCNJ2 0.334 1.40 1.04-1.87 0.02 
 
Table 3.3: Multivariate Cox hazard analysis for 8 candidate genes 
 
Coefficients Hazard ratio 95%CI P value 
GJA1 -0.09 0.90 0.53-1.53 0.72 
CXCR7 0.01 1.01 0.64-1.59 0.96 
NID2 0.37 1.45 0.88-2.38 0.14 
PLXDC1 0.53 1.71 1.07-2.72 0.02 
EFNB2 -0.04 0.95 0.57-1.59 0.86 
KCNJ2 0.48 1.62 1.03-2.59 0.03 
 
Based on the multivariate Cox hazard results, a model was built combining the 
expression analysis of both genes, PLXDC1 and KCNJ2 which were 
significant in the multivariate Cox hazard analysis. This resulted in the 
multivariate-based risk score y =0.598 PLXDC1+0.520 KCNJ2. In datasets 
GSE14520 and TCGA-LIHC, the risk score of patients was calculated by this 
model. Patients with high-risk score had a lower 5-year survival rate in both 
independent cohorts confirming that PLXD1 and KCNJ2 may be used as risk 
factors in HCC (Figure 3.22; P<0.05). This evidence suggested that GJA1, 
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PLXDC1, KCNJ2, CXCR7, NID2, and EFNB2, may be potential c-KIT targeted 
genes, may be involve disease progression and my result in poor prognosis of 
HCC patients. 
 
Figure 3.22: Model obtained from Cox hazard analysis may predict patient 
prognosis. the risk score y =0.598 PLXDC1+0.520 KCNJ2 was built based on Cox 
hazard analysis which reflects the risk for poor prognosis of HCC patients. In dataset 
GSE14520 and TCGA-LIHC, the risk score of patients was calculated by this model 
Kaplan-Meir curves of patients with high risk or low risk score are depicted. P value 
was estimated by the log-rank test. 
Furthermore, the expression of the 8 selected c-KIT-related candidate genes 
was analyzed in an RNA sequencing dataset of 8 different HCC cell lines 
(unpublished data of AG Rössler, Figure 3.23). According to the endogenous 
c-KIT expression, HCC cell lines were grouped based on their endogenous 
c-KIT expression as negative and positive cell lines. The difference in the 
expression of the 8 candidate genes between c-KIT+ and c-KIT– HCC cell 
lines revealed that PLXDC1, KCNJ2, JAM3, and GJA1, were higher in 
endogenous c-KIT-positive HCC cell lines which is in concordance with the 
results of the patient expression profiles.  
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Figure 3.23: Expression difference of 8 candidate genes between endogenous 
c-KIT-positive and negative HCC cells. (A) Based on the RNA sequencing data, 
eight HCC cell lines were grouped c-KIT-negative and positive cell lines. The 
expression profiles of 8 potential c-KIT related genes were shown as a heat map. (B) 
The relative fold changes of 8 candidate genes between c-KIT-positive and negative 
HCC cells were calculated. 
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Furthermore, the correlation coefficient between c-KIT and PLXDC1, KCNJ2, 
JAM3, or GJA1 was calculated by Pearson Correlation analysis using the data 
from GSE14520 and matched Gene Ontological (GO) biological process terms 
were inquired from the database of Gene Ontology Consortium 
(http://www.geneontology.org/). The GO biological process terms of PLXDC1, 
KCNJ2, JAM3, and GJA1 included cell adhesion, bicellular tight junction and 
response to a mechanical stimulus which could be associated with cell 
migration. Statistically significant correlation of c-KIT with PLXDC1, KCNJ2, 
JAM3, and GJA1 were observed (Figure 3.24). 
 
Figure 3.24: Gene Ontological (GO) biological process terms of four potential 
c-KIT targeted genes and the correlation with c-KIT expression levels in HCC 
tissues. The GO biological process terms of PLXDC1, KCNJ2, JAM3, and GJA1 
included focal adhesion, cell adhesion, bicellular tight junction and response to 
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mechanical stimulus. Statistically significant correlation of c-KIT with PLXDC1, KCNJ2, 
JAM3, and GJA1 are shown in the table of the bottom right corner. 
 
Combining the evidence obtained from the patients datasets and the HCC cell 
lines, PLXDC1, KCNJ2, JAM3, and GJA1 were selected forvalidation in vitro. 
Thus, c-KIT expression of HLE, SNU-182 and HLF cells was knockeddown 
using siPool. the mRNA level changes of PLXDC1 KCNJ2, JAM3, and GJA1, 
were measured by qRT-PCRJAM3 and GJA1 decreased after c-KIT 
knock-down in both three cell lines that resulted as expected (Figure 3.25). 
However, the PLXDC1 mRNA level increased in c-KIT silenced HLE and HLF 
cells. The KCNJ2 mRNA was not changed in c-KIT knock-down HLF cells. 
The data mentioned above indicated that c-KIT might regulate some of the 
genes such as PLXDC1, KCNJ2, JAM3 and GJA1 which were correlated with 
the prognosis of patients with HCC. c-KIT may also promote migration through 
these genes. However, further investigation needs to prove this hypothesis. 
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Figure 3.25: PLXDC1, KCNJ2, JAM3 and GJA1 expression changes after c-KIT 
knock-down HCC cell lines. c-KIT expression of HLE (A), SNU-182 (B) and HLF (C) 
cells was knocked-down by siPool. the mRNA level changes of PLXDC1 KCNJ2, 
JAM3, and GJA1, were measured by qRT-PCR. Data were normalized by 
HSCF-treated and siPool control transfected cells and presented as mean ± SD of 
technical duplicates. *P<0.05 compared with siPool control transfected cells in each of 
condition. 
  
DISCUSSION 
79 
 
4. DISCUSSION 
HCC is a leading cause of cancer-related deaths and characterized by a 
growing incidence worldwide (Cadier et al., 2017). Despite the implementation 
and improvement of screening for high-risk individuals, most HCC patients are 
diagnosed in an advanced stage which means that current curative treatment 
options (e.g., liver transplantation, liver resection, and ablative procedures) 
cannot be applied Hence, the median overall survival for advanced cases 
remains poor (Raza and Sood, 2014).The advent and application of 
molecularly targeted therapy have created an encouraging trend in the 
management of some advanced cancer patients. For example, a benefit for 
the survival of advanced non-small lung cancer patients provided by diversified 
targeted drugs has been well demonstrated (Lategahn et al., 2018). However, 
the development of HCC targeted drugs has failed so far. Currently, Sorafenib, 
a multi-targeted kinase inhibitor, is the only drug proven to improve the 
outcome of patients with advanced HCC providing an overall survival benefit of 
2-3 months (Ardelt et al., 2018). The last few years have witnessed the failure 
of several first and second line phase III clinical trials of novel molecularly 
targeted therapies. To dissolve this misery, expanded molecular and functional 
knowledge of the potential target of HCC therapy in drug development is 
urgently needed (Fujiwara et al., 2018). 
The receptor tyrosine kinase c-KIT has been reported to function as an 
oncogene and to play a crucial role in the development of some cancer entities. 
Evidence shows that aberrantly activated c-KIT promotes cell proliferation and 
survival in several cancers (Lamarca et al., 2013). Promising results of using 
c-Kit as a therapeutic target for treatment of cancers have been observed in 
GIST, AML, melanoma and colorectal cancer (Shah and van den Brink, 2015; 
Stankov et al., 2014). However the limitations in clinical application of using 
c-KIT as target cannot be ignored. For example, in GIST c-KIT inhibitors are 
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effective only when treating c-KIT wildtype or specific mutations (e.g., D816V.) 
(Noujaim et al., 2016). A number of c-KIT mutations (e.g., D816V and D816Y) 
may result in resistance to imatinib but are sensitive to other tyrosine kinase 
inhibitors (Growney et al., 2005). Hence exploring more mutations of c-KIT and 
identifying their matched inhibitors are imperative as well as further studies in 
functions of wild-type c-KIT. Upon activation through binding of stem cell factor 
(SCF), c-KIT exerts its function by intracellular signaling transduction. The 
typical downstream signalings of c-KIT include the MAPK pathway, PI3K/AKT, 
and Jak-STAT signaling which are pathways affected in hepatocarcinogenesis. 
Thus, c-KIT may be involved in HCC and therefore, it may also be a key 
therapeutic target for HCC (Salgado et al., 2014). However, the role of c-KIT in 
HCC has been poorly studied, and results about c-KIT in HCC were 
inconsistent in previous studies. From the perspective of personalized 
medicine and precision medicine, c-KIT can be considered as an ideal target 
as it is a receptor with kinase activity. Therefore, I investigated the functional 
role and related mechanisms of c-KIT and its mutations in HCC. In addition, 
the correlation of c-KIT with patients’ prognosis was considered to test if c-KIT 
may also be used as a molecular marker. 
4.1 Expression of c-KIT in tissue samples from patients with HCC and its 
clinical relevance 
To make sure that the knowledge of c-KIT could be applied to clinical practices, 
firstly, I estimated the expression feature of c-KIT in tissue samples from a 
patient with HCC and analyzed the correlation of c-KIT with clinical characters 
such as stage and prognosis. For this analysis, gene expression dataset of 
HCC patients with a relatively large sample size were downloaded from the 
GEO (GSE14520, GSE76427, GSE36376 and GSE76297) and TCGA-LIHC 
databases. This included a total of 1148 HCC samples from different 
geographical regions (China, South Korea, Singapore and Thailand) and with 
different etiologies (HBV- related or not).  
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In all four datasets, c-KIT was statistically higher in tumor tissues compared to 
non-tumor tissues. For dataset GSE14520, patients BCLC and CLIP staging 
were available. Patients with advanced stage had higher c-KIT expression 
(P<0.05). This indicates that c-KIT may be involved with the progression of 
HCC. The elevated expression of c-KIT in tissues and the increased 
expression in patients with higher stage supported the potential oncogenic role 
of c-KIT in HCC. The mean difference in c-KIT expression between tumor and 
non-tumor tissues was relatively small which may be the result of the high 
heterogeneity among HCC patients. Some patients had high induction of c-KIT, 
which may indicate that they represent a specific subgroup of HCC patients. 
Using the median value of c-KIT in tumor tissues as cut-off I grouped patients 
with HCC into patients with high or low c-KIT expression level. Because the 
clinical information was not available for two datasets, I only analyzed the 
correlation of c-KIT with prognosis in the dataset GSE 14520 (Roessler et al.) 
and the TCGA-LIHC dataset. I found that patients with higher c-KIT expression 
had poorer prognosis. When using the third quartile as a cut-off, the difference 
on survival rate because more significant suggesting that one quarter of 
patients fall in a subgroup of patients with most relevant c-KIT expression 
(data not shown). Until now characterization of c-KIT expression and its clinical 
relevance in HCC were only reported in few studies. Yan et al. showed that 
48.1% of cases expressed c-KIT in a cohort consisting of 206 HCC cases. 
High c-KIT expression was considered an independent unfavorable prognostic 
factor for patients with HCC (Yan et al., 2018). However, other studies did not 
confirm this relatively high number of c-KIT positive HCC cases. Becker et al. 
reported that the overall c-KIT-positive rate in HCCs was only 2.3%. Hence, 
they suggested that c-KIT is not significantly overexpressed in HCC. But this 
study did not use non-tumor tissue as a control (Becker et al., 2007). Chung et 
al. reported that 26% of HCC tissues are c-KIT-postive And they found that in 
contrast to Yan et al. high c-KIT correlated with better prognosis (Chung et al., 
2005). Thus, available studies on c-KIT expression in HCC tumor tissues and 
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on the clinical relevance of c-KIT expression on patient prognosis are 
inconsistent. 
Potential underlying problems are the use of different antibodies, the lack of 
reference tissue to analyze the relative expression and the overall high 
heterogeneity within and between the HCC cohorts. As these results were 
obtained by immunohistochemical staining, the discrepant results may be 
caused by a wide variety of antibody quality, staining or scoring protocols. 
Another potential reason includes the cellular heterogeneity of HCC or the 
distinct stages of cell differentiation. These limitations did not apply to our 
analysis using mRNA expression profiles of HCC tumor and non-tumor tissues 
which supported the hypothesis that c-KIT is involved in the HCC progression 
and be function as an oncogene. Hence, functional assays were performed to 
analyze the role of c-KIT on cell migration and proliferation.  
4.2 Mutations of c-KIT in patients with HCC 
Deregulation of c-KIT expression in tumorigenesis may be caused by aberrant 
epigenetic regulation or mutations (Abbaspour Babaei et al., 2016). Some 
mutations of c-KIT (such as V560G and L576P) lead to disruption of 
auto-inhibitory mechanisms, inducing dimerization and continuous activation of 
kinase domains which subsequently induce excessive activation of 
downstream pathways. Hence these mutations are regarded as activating or 
gain-of-function mutations (Ashman and Griffith, 2013). The most striking 
involvement of c-KIT mutation is observed in GIST. More than 80% of GIST 
cases display activating c-KIT mutations resulting in constitutive activation. 
Constitutive activation of c-KIT signaling caused by activating mutations of 
c-KIT are also observed in AML (Beghini et al., 2004). In these cases c-KIT 
mutations play a main role in the initiation of tumorigenesis inhibiting the c-KIT 
kinase activity may be a target for cancer therapy. In contrast, in some cases of 
melanoma and breast cancer inactivating or loss-of-function mutations of c-KIT 
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were observed (Eigentler et al., 2013; Tsutsui et al., 2006). In these cases, 
c-KIT inhibition most likely would not have any benefit and may even have 
adverse effects. To meet the need for personalized medicine and precision 
medicine, the molecular function and mechanisms underlying specific c-KIT 
mutations need to be clarified. 
For HCC, mutations of c-KIT have not yet been studied. Recent large scale 
genome sequencing projects enabled us to search for c-KIT mutations in large 
HCC cohorts. A relative low frequency of c-KIT mutations was observerd. 
For instance, in the TCGA-LIHC dataset, the frequency of c-KIT mutation was 
2.8% (10/357). In the HCC data set of the Asian Medical Center (AMC), only 
0.83% of HCC patients had c-KIT mutations. In Catalogue of Somatic 
Mutations in Cancer database (COSMIC, https://cancer.sanger.ac.uk/cosmic) 
1057 cases were included which combined the TCGA-LIHC dataset with other 
genome-wide screens. But only thirteen cases with c-KIT mutations were 
detected in these 1057 HCC patients. However, no publication has so far 
identified the role of specific c-KIT mutations in HCC patients. In DKFZ-HIPO 
(Heidelberg Center for Personalized Oncology) project 14, I analyzed 57 HCC 
patients by whole exome sequencing. Among the 57 HCC patients, three 
different c-KIT mutations, W262C, C674F, and L766I, were found in one 
patient each. All three mutations were validated by Sanger sequencing and 
confirmed to be somatic Thus, all three mutations are tumor specific and 
missense mutations. The c-KIT mutations C674F and L766I lie in exon 14 and 
exon 15, respectively. Exon 14 and exon 15 encode the kinase domain of c-KIT. 
These two mutations may influence the phosphorylation of c-KIT. The mutation 
W262C is in exon 5 which encodes the third lg-like domain of c-KIT. Hence this 
mutation may impact the binding of SCF. To select the most probably 
functional mutations, I predicted the possible impact of these mutations on the 
structure and function of c-KIT using PolyPhen 2.0. The W262C and C674F 
DISCUSSION 
84 
 
mutations yielded a high PolyPhen score which suggested an impact on 
protein structure and function. As the L766I mutation had a score 0 which 
implicated that the protein structure and function are not affected by this 
mutation, it was not included in further analyses. I tried to test whether these 
mutations are activating mutations or inactivating mutations. Moreover, their 
function on proliferation and migration of HCC cell lines was determined. 
4.3 The endogenous expression of c-KIT IN different HCC cell lines 
I selected appropriate HCC cell lines for further analysis according to the 
endogenous expression of c-KIT. The endogenous c-KIT expression among 
nine HCC cell lines was detected by Western blot and qRT-PCR. Results 
showed that the endogenous expression of c-KIT was completely absent or 
present. An unknown feedback mechanism might play a role to ensure the 
optimal c-KIT level that can facilitate the growth of specific cells. In addition, 
the different endogenous expression of c-KIT may be caused due to the 
heterogeneity of HCC. Thus, HCC cells coming from different origins may have 
different endogenous c-KIT levels. This could also explain why in previous 
studies inconsistent rates of c-KIT-positive HCCs were reported. In 
c-KIT-negative cell lines, the c-KIT-related downstream signaling pathways 
may also be defective as they are not required for the tumor cell. Hence in 
these cell lines only overexpression of c-KIT may not cause any expected 
phenotypic changes. In a clinical perspective, absent expression of c-KIT may 
be a barrier for the clinical application when using c-KIT inhibitors.  
4.4 The effect of c-KIT expression alteration and mutations on relevant 
downstream pathways in HCC cell lines 
As a tyrosine kinase receptor, the main function of c-KIT is mediating 
downstream intracellular signaling transduction by inducing phosphorylation. 
In the present work, the effect of c-KIT expression alteration and mutations on 
relevant downstream pathways in HCC cell lines was investigated by 
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measuring the phosphorylation level of relevant components. Frequently 
reported and HCC-related downstream signaling pathways of c-KIT are 
PI3K/AKT, MAPK, and JAK/STAT pathways (Figure 4.1). Few reports showed 
the downstream regulating pattern of c-KIT in HCC. Moreover, it is necessary 
to examine the effect of mutations on downstream signaling. Hence these 
three pathways were investigated in this thesis work. 
 
Figure 4.1: Schematic model of downstream pathways regulated by c-KIT. The 
binding of SCF to the c-KIT receptor results in activation of the MAPK signaling 
pathway, the PI3K/AKT pathway and the JAK2/STAT pathway. 
Firstly, I examined the activation changes of c-KIT after HSCF treatment in 
HCC cell lines. c-KIT/W262C overexpressing HUH7, and HEP3B cells showed 
significantly lower p-c-KIT level, compared with cells with c-KIT/WT and 
c-KIT/C674F. this indicated that the W262C mutation inhibits HSCF-induced 
activation of c-KIT. The W262C mutation is located in exon 5 of c-KIT cDNA 
which encodes the third lg-like domain. Therefore, I hypothesized that W262C 
might interfere with the HSCF binding. c-KIT/C674F showed no difference in 
the activation of c-KIT. As expected, p-c-KIT was reduced in c-KIT 
siPool-treated HCC cells due to the effective knock-down of total c-KIT protein 
expression. 
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Next, I analyzed the phosphorylation level of AKT to reflect the changes on 
PI3K/AKT signaling. PI3K/AKT signaling, which is subsequently activated by 
phosphorylation of c-KIT, is the most reported pathway involving c-KIT (Zhang 
et al., 2011). Activation of PI3K/AKT mediated an apoptosis inhibitory and 
proliferation promoting effect of c-KIT/SCF signaling in GIST (Chen et al., 2017) 
and AML (Yu et al., 2016). As expected, increasing p-AKT was observed in 
c-KIT overexpressing HCC cells but not found in c-KIT knock-down cells. 
However, the p-AKT levels increased significantly less in c-KIT/W262C 
expressing cells compared to c-KIT/WT and c-KIT/C674F. This evidence 
indicated that the PI3K/AKT signaling is efficiently regulated by c-KIT in HCC 
and may be impaired by c-KIT/W262C mutation.  
The MAPK family consists of highly conserved serine/threonine protein 
kinases involved in proliferation, motility, and cell survival in HCC. Todd et al. 
showed that oncogenic c-KIT mutants contribute to the progression of some 
melanomas by activating MAPK signaling (Todd et al., 2014). Here, I examined 
the phosphorylation level of ERK1/2 and JNK in HCC cell lines and found that 
ERK1/2 increased and JNK signaling is activated by c-KIT signaling through 
stimulation with HSCF. However, c-KIT mutation W262C led to reduced JNK 
activation. Thus, the observed low c-KIT phosphorylation levels of 
c-KIT/W262C did not efficiently activate downstream MAPK signaling. 
Finally, I investigated the activation changes of JAK/STAT signaling. The 
JAK/STAT pathway is a pleiotropic cascade used to transduce signals, 
involved in the tumor formation and proliferation in HCC (Wen et al., 2018). 
Calvisi et al. demonstrated the importance of the constitutive activation of the 
JAK/STAT signaling in the development of HCC and found that negative 
regulators of JAK/STAT signaling showed growth-suppression activity (Calvisi 
et al., 2006). Here, the phosphorylation level of JAK2, STAT1, and STAT3 were 
detected. Previous studies showed that c-KIT could elicit the activation of 
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STAT1 and STAT3 through activating JAK2 (Deberry et al., 1997; Linnekin et 
al., 1996). However, I observed varying effects. In HUH7 cells, only wild-type 
c-KIT overexpressing cells showed increased p-STAT1 level. The p-STAT3 
level was decreased in c-KIT/WT, c-KIT/C674F and c-KIT/W262C 
overexpressing cells which is inconsistent with previous studies in other tumor 
entities. In HEP3B the phosphorylation level of STAT1 and STAT3 were like in 
previous studies. The W262C mutation also showed less effects as well as 
results obtained from PI3K/AKT and MAPK signaling. No significant difference 
in p-JAK2 was found in each condition. As Chaix et al. showed, JAK3 rather 
than JAK2 induced the activation of STAT1 and STAT3 in neoplastic mast cells 
with oncogenic KIT mutants (Chaix et al., 2011). Hence, I assume that STAT1 
and STAT3 were regulated by other members of JAK family excepting JAK2 in 
HUH7 and HEP3B. So far, I did not detect expression changes of JAK2 and 
JAK3 expression after c-KIT overexpression or knock-down. The lack of good 
Western blot antibodies against additional JAK family members prevented 
further analyses. It is a limitation of this work. On the other hand, I found the 
p-JAK2 level was decreased in c-KIT knock-down HLE and SNU-182 cells. 
However, I obtained inconclusive results for p-STAT1 and p-STAT3 changes 
upon knock-down of endogenous c-KIT. The p-STAT1 and p-STAT3 level 
decreased after stimulation with HSCF in a c-KIT-independent way. The 
knock-down of c-KIT in all three HCC cell lines tested did not alter the p-STAT1 
and p-STAT3 levels. Taken together, it appears that p-STAT1 and p-STAT3 
level is not a significant downstream pathway of c-KIT signaling in HCC cells. 
In summary, c-KIT activated PI3K/AKT and MAPK pathways in HCC cells. 
However, c-KIT’s role in JAK/STAT signaling still remains unclear. Most 
importantly, I confirmed that C674F is not an activating mutation and W262C 
mutation appears to be an inactivating mutation of c-KIT. Tsutsui et al. showed 
loss of c-KIT expression is associated with an advanced stage and poor 
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prognosis in breast cancer Tsutsui et al., 2006). Thus, c-KIT inactivation may 
be clinically relevant. 
4.5 The effect of c-KIT expression alteration and mutations on the 
proliferation and migration of HCC cell lines 
Oncogenic c-KIT activation caused by overexpression or mutation could 
promote proliferation and migration in cancers through regulating various 
downstream pathways. Yasuda et al. showed proliferation and invasion were 
significantly enhanced in c-KIT-positive pancreatic cancer cells (Yasuda et al., 
2006). In the other study, they also found c-KIT may enhance the proliferation 
and invasion in colorectal cancer cells (Yasuda et al., 2007). In c-KIT-positive 
small cell lung cancer cells, SCF increased cellular proliferation. Inhibition of 
PI3K/AKT signaling could alleviate this effect (Kijima et al., 2002) In HCC, 
Rojas et al. showed that activating of c-KIT/JAK1/STAT3 axis induces 
migration of HCC combining with TGF-β related signaling(Rojas et al., 2016). 
To our knowledge, except the study by Roja et al. until now there is no other 
direct evidence showing whether c-KIT controls proliferation or migration in 
HCC cell lines. 
In this thesis work, I investigated the effect of c-KIT overexpression and 
knock-down. Surprisingly, in HUH7 and HEP3B cells overexpression of c-KIT 
could not promote proliferation even with the HSCF stimulation. Certainly, no 
significant difference between wild-type and mutated c-KIT was found. On the 
other hand, knock-down of c-KIT in HLE, SNU-182, and HLE did not inhibit the 
proliferation compared with control cells. Moreover, HSCF did not induce more 
proliferation in control cells which had enough endogenous c-KIT. I adjusted 
seeding density, the time point for measurement and time of duration for HSCF 
treatment. One possible reason is that the proliferation of these HCC cell lines 
is relatively fast. It may be hard to promote the proliferation further. In this way, 
the effect of c-KIT on the proliferation of these cells may be slight and hard to 
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detect. In preliminary experiments, I examined the cell cycle changes in Huh7 
and HLF cells, respectively but no significant difference was found in this 
analysis (data not shown). Thus, c-KIT had no effect on the proliferation of 
HCC cells. 
To avoid interference from proliferation, HCC cells were cultured in the 
serum-free medium after scratching in the migration assay. In HUH7 cells, 
overexpression of wild-type c-KIT significantly promoted cell migration. The 
two mutant forms of c-KIT also promoted slightly faster migration but without 
statistical difference. The migration-promoting effect of c-KIT overexpression 
could be observed without HSCF treatment and HSCF treatment did not 
enhance this effect. This might be explained by autocrine SCF which could 
induce enough c-KIT activation in c-KIT overexpressing HCC cells. Another 
mechanism might be the enhanced dimerization of c-KIT due to ectopic 
overexpression of the receptor. Interestingly, in HEP3B I observed an opposite 
result. Wild-type c-KIT inhibited migration and mutant c-KIT had no effect on 
migration. 
Thus, the analysis of c-KIT knock-down might be a more physiological model 
of c-KIT function in HCC cells. HSCF stimulation promoted migration in HLE, 
SNU-182, and HLF which was not observed in c-KIT knock-down cells. 
Without HSCF stimulation no difference was found between c-KIT knock-down 
cells and control cells. In addition, in control knock-down cells HSCF had a 
positive effect on cell migration. Thus, the three c-KIT-positive cell lines, HLE, 
SNU-182 and HLF, cell migration was reduced by lack of HSCF or by c-KIT 
knock-down. This result may suggest that in HLE, SNU-182, and HLF 
autocrine HSCF levels and the endogenous c-KIT might be too low in the 
serum-free medium to promote c-KIT activation. Hence in another migration 
assay, cells were cultured in medium with 10% FCS to prove our assumption. 
This confirmed that even without HSCF-treatment a significant difference was 
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observed between c-KIT knock-down and control cells with c-KIT knock-down 
cells showing slower migration. In summary, functional assays showed that 
SCF/c-KIT signaling may promote cell migration. 
4.6 c-KIT regulated EMT in HCC cell lines 
To explain the molecular mechanism how migration was regulated by c-KIT 
activation in HCC cell lines, I analyzed changes of EMT markers. EMT is 
defined as trans-differentiation of stationary epithelial cells into motile 
mesenchymal cells. During EMT a series of changes such as cell junction loss, 
cytoskeleton reorganization and gene expression reprogramming occur which 
increase the migration of individual cells and enables the development of an 
invasive phenotype (Meng et al., 2018). Numerous studies have reported that 
some genes influence the migration of HCC cells in vitro through regulating 
EMT (Ibrahim et al., 2017; Zhou et al., 2018). It has been confirmed that EMT 
plays a crucial role in the early steps of metastasis in HCC and affects the 
clinical outcome of patients (Giannelli et al., 2016). Tang et al. found a 
significant association between the positive expression of c-KIT and EMT in 
salivary adenoid cystic carcinoma (ACC). They indicated that c-KIT 
participates in the invasion and metastasis of salivary ACC by promoting EMT 
(Tang et al., 2010). A panel of cell-surface proteins, cytoskeletal proteins, and 
transcription factors, involved in the occurrence of EMT, are regarded as EMT 
markers. Their function and more details could be seen in Zeisberg’s review 
(Zeisberg and Neilson, 2009). Here, I examined the mRNA level of seven EMT 
markers including Snail1, Twist1, CDH1 (E-cadherin), CDH2 (N-cadherin), 
Vimentin, ZEB1, and ZEB2. In HUH7 c-KIT overexpression increased the 
mRNA level of Twist and Vimentin. In HEP3B ZEB1 decreased and no other 
EMT markers changed. This could be used to explain why c-KIT 
overexpressing HEP3B cells showed opposite effects of HUH7. In c-KIT 
knock-down HLE, SNU-182 and HLF cells, decreased mRNA levels of Snail1, 
Vimentin, N-cadherin and ZEB1 were found. Collectively, I suggested that 
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c-KIT could control the migration of HCC cells through regulating EMT. 
However, to make this evidence stronger the protein level of the EMT markers 
needs to be examined in the future. 
4.7 Selection and validation for candidate gene regulated by c-KIT 
I also sought to identify novel genes which may be regulated by c-KIT. To 
achieve this goal, I analyzed a series of datasets from HCC patients. In three 
large datasets from GEO and the TCGA-LIHC dataset, differentially expressed 
genes (DEGs) between patients with high c-KIT level and patients with low 
c-KIT level were extracted. Finally, PLXDC1, KCNJ2, JAM3, and GJA1 were 
selected as candidate c-KIT-regulated genes, as these four genes were higher 
in patients with high c-KIT level. A limitation of the tissue analysis is that HCC 
tumor tissues contain a mixture of different cell types. It cannot be pinpointed 
which cells express the measured genes. Also it cannot be ruled out that the 
here identified genes are upstream of c-KIT or are co-regulated by unknown 
mechanisms. The advantage of such gene expression studies is the high 
sample number and that the candidate genes obtained from patient tissues 
might have high clinical relevance and may be closer to the potential of clinical 
application. Furthermore, I found that these genes associated with prognosis 
of patients with HCC. This underpinned that the identified genes may be 
relevant in HCC. Bioinformatic query of cellular functions suggested that these 
genes may be involved with cancer-associated biological process (e.g. cell 
adhesion). However, the function of these genes needs to be confirmed in 
further experiments in HCC. It is not clear if these genes are up or downstream 
of c-KIT. In this work, only mRNA level of KCNJ2, JAM3, and GJA1 inhibition 
was observed in c-KIT silenced HCC cells. Unfortunately, in c-KIT 
overexpressing HCC cells, the regulatory effect of c-KIT on these genes could 
not be confirmed. One possible reason is that c-KIT could only regulate these 
genes through specific downstream pathway but c-KIT-negative cells may lack 
these downstream pathways. Although c-KIT was overexpressed in these cells, 
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due to the lack of specific downstream pathways, the regulatory function could 
not be performed. Another reason might be that I only tested the expression 
changes of these genes after c-KIT overexpression at a single time point. 
Longer time points might be necessary for indirect effects. Thus, the analysis 
of four large gene expression data sets including a total of 970 patients 
(GSE22058,GSE25097,GSE14520 and TCGA-LIHC), resulted in the 
identification of the c-KIT co-regulated genes PLXDC1, KCNJ2, JAM3, and 
GJA1 of which KCNJ2, JAM3, and GJA1 could be validated in vitro by c-KIT 
knock-down. 
4.8 Outlook 
So far, the data generated in this work partly revealed the role of c-KIT and 
encouraged further study. I found c-KIT could promote migration of HCC cells 
in vitro the possible mechanism may be involved with EMT. Apart from that 
several genes which may be regulated by c-KIT were selected and verified in 
virto. Black boxes of molecular mechanism obstruct us to acquire the overall 
perspective about the role of c-KIT in HCC. To light up the black boxes, further 
experiments should be designed. 
I have already confirmed that PI3K/AKT and MAPK pathways have been 
activated by c-KIT/SCF in HCC cell lines. Meanwhile, I found that c-KIT 
promoted migration of HCC cell lines. However, present data did not show a 
link between the PI3K/AKT or MAPK pathways between c-KIT’s migration 
regulatory effect. I plan to use specific chemical inhibitors to suppress the 
activation of PI3K/AKT or MAPK pathways and then observe whether the 
migration regulatory effect of c-KIT still retains. Excepting PI3K/AKT and 
MAPK pathways, in future more potential downstream pathways regulated by 
c-KIT should be revealed. To achieve this goal, a human phospho-kinase 
antibody array will be used to explore more proteins that can be 
phosphorylated by c-KIT. I have already found c-KIT regulated EMT in HCC 
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cell lines that could be used to partly explain how c-KIT promotes cell migration. 
Based on the patient's data I selected and validated several candidate genes 
that may be regulated by c-KIT. Next, I will investigate whether these genes 
are involved in HCC cell migration through functional rescue experiments. 
RNA microarray profiling will be performed using c-KIT up- or down-regulated 
HCC cells to discover more genes targeted by c-KIT. Noncoding RNA such as 
microRNA or LncRNAs will be also considered in microarray assay. Finally, 
until now all presented data in this thesis are restricted to in vitro settings. To 
address this limitation the role of c-KIT will be examined in an orthotopic 
mouse model using hydrodynamic tail vein injection. 
In conclusion, high c-KIT levels correlated with the stage of HCC and indicated 
poor patients outcome. In vitro, c-KIT activated PI3K/AKT or MAPK pathways 
in HCC cell lines. The patient-derived c-KIT mutations W262C, and C674F 
mutations were found to inactivate c-KIT’s function limiting the clinical 
application in HCC. Wildtype c-KIT increased cell migration through regulating 
EMT. c-KIT which suggests that overexpression of wildtype c-KIT might be 
clinically relevant. Thus, c-KIT might be a therapeutic option for specific 
patients with c-KIT-high HCC tumor tissue. 
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5. SUMMARY 
Hepatocellular carcinoma (HCC) is the most common primary hepatic 
malignancy and second leading cause of cancer-related deaths worldwide. 
Despite recent advances in diagnosis and molecular understanding, limited 
success was obtained in improving the survival of HCC patients. Molecular 
targeted therapies provide an opportunity to expand life expectancy of patients. 
However, up to now only sorafenib, a multikinase inhibitor, showed survival 
benefits in some patients. Thus, there is an urgent demand to discover novel 
molecular targets in HCC to improve therapeutic outcome. As a receptor 
tyrosine kinase, c-KIT participates in intracellular signaling. Aberrant 
expression or mutation of c-KIT plays an oncogenic role and inhibition of c-KIT 
has shown promising results in some cancer. However, the role of c-KIT in 
HCC is still unclear and the potential of utilizing c-KIT as a therapeutic target in 
HCC needs to be assessed. Thus, the main aim of this thesis was to analyze 
the functional role of c-KIT and illuminate its relevant mechanism in the 
progression of HCC. 
Using public datasets of patients with HCC, the clinical relevance of c-KIT was 
analyzed. In vitro, activation of downstream pathways which are regulated by 
c-KIT was investigated. Moreover, functional analysis was performed using 
c-KIT overexpression and knock-down in HCC cell lines. Meanwhile, two 
patient derived mutations of c-KIT (W262C and C674F) were considered in the 
process of analysis. Based on RNA microarray data from patients and RNA 
sequencing data from HCC cells, candidate genes that are regulated by c-KIT 
were selected and validated using bioinformatics methods and in vitro 
experiments. The results showed that high c-KIT indicated poor outcome of 
patients. c-KIT activation regulated PI3K/AKT and MAPK pathways in HCC 
cells. No effect of c-KIT on proliferation was observed, but the migration of 
HCC cell lines was promoted by c-KIT possibly by induction of 
epithelial-mesenchymal transition. The c-KIT mutation W262C led to loss of 
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functional c-KIT signaling. The analysis of large HCC gene expression data 
sets revealed the genes PLXDC1, KCNJ2, JAM3, and GJA1 which may be 
regulated by c-KIT. Interestingly, PLXDC1, KCNJ2 and GJA1 expression 
correlated with prognosis of HCC patients and their function is very likely 
involved in cell migration. Taken together, the data presented here support that 
c-KIT plays an oncogenic role in HCC and targeting c-KIT may benefit patient 
outcome.  
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Zusammenfassung 
Das hepatozelluläre Karzinom ist die häufigste primäre Tumorerkrankung der 
Leber und die zweithäufigste Tumor-bedingte Todesursache weltweit. Trotz 
Fortschritten in der Diagnose und dem molekularen Verständnis von HCC, hat 
sich das allgemeine Überleben von HCC Patienten nur leicht verbessert. 
Molekulare zielgerichtete Therapien bieten die Möglichkeit die 
Lebenserwartung von Patienten zu erhöhen. Bisher konnte jedoch nur für den 
Multi-Kinase-Inhibitor Sorafenib ein verbessertes Überleben in manchen HCC 
Patienten gezeigt werden. Aus diesem Grund besteht ein großer Bedarf neue 
molekulare Zielstrukturen im HCC zu identifizieren, um den Therapieerfolg zu 
verbessern. Die Rezeptortyrosinkinase c-KIT partizipiert in der intrazellulären 
Signaltransduktion. Die veränderte Expression oder Mutation von c-KIT spielt 
eine onkogene Rolle und die Inhibition von c-KIT zeigte in manchen 
Tumorentitäten vielversprechende Ergebnisse. Die Rolle von c-KIT im HCC ist 
jedoch noch unklar und die potentielle Verwendung von c-KIT als 
therapeutisches Ziel im HCC muss noch untersucht werden. Deshalb war das 
Ziel der vorliegenden Arbeit die Funktion von c-KIT und die relevanten 
Mechanismen der Progression des HCC zu untersuchen. 
Unter Verwendung von öffentlichen Datensätzen von HCC Patienten wurde 
die klinische Relevanz von c-KIT untersucht. Die Aktivierung von 
nachfolgenden Signaltransduktionswegen von c-KIT wurde in vitro untersucht. 
Zusätzlich wurden funktionale Analysen mittels Überexpression und 
Inhibierung der c-KIT Expression in HCC Zelllinien durchgeführt. In HCC 
Patienten konnten vereinzelt c-KIT Mutationen gefunden werden. Zwei c-KIT 
Mutationen, W262C und C674F, wurden im Rahmen dieser Arbeit untersucht. 
Basierend auf RNA Microarraydaten und RNA Sequenzierungsdaten von HCC 
Patienten, wurden Gene, die potentiell durch c-KIT reguliert werden, 
bioinformatisch identifiziert und mittels in vitro Experimenten validiert. Eine 
hohe c-KIT Expression korrelierte mit schlechtem Überleben und die 
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Aktivierung von c-KIT induzierte die PI3K/AKT und MAPK 
Signaltransduktionswege. Es konnte kein Effekt auf die Zellproliferation von 
HCC Zellen beobachtet werden, aber die Zellmigration wurde durch c-KIT 
erhöht, was möglicher Weise durch die Induktion von 
Epithelial-Mesenchymaler-Transition erklärt werden kann. Die c-KIT Mutation 
W262C führte zu einem Funktionsverlust der c-KIT Signaltransduktion. 
Anhand großer Genexpressionsdatensets wurden PLXDC1, KCNJ2, JAM3 
und GJA1 als mit c-KIT koregulierte Gene identifiziert, und diese wurden nach 
c-KIT knock-down vermindert exprimiert. Des Weiteren korrelierte die 
Expression von PLXDC1, KCNJ2 und GJA1 mit vermindertem Überleben und 
diese Gene spielen wahrscheinliche eine Rolle in der Zellmigration. 
Zusammenfassend zeigen diese Ergebnisse, dass c-KIT eine onkogene Rolle 
im HCC spielt und dass die Hemmung von c-KIT in diesen Patienten möglicher 
Weise das Überleben dieser Patienten verbessern könnte.  
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